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ABSTRACT
Biomarker Analysis and Clinical Significance of Thymidine Kinase 1 in Solid and
Hematological Malignancies
Evita Giraldez Weagel
Department of Microbiology and Molecular Biology, BYU
Doctor of Philosophy
Despite the global effort to discover and improve ways to detect, treat, and monitor
cancer, it still remains the second leading cause of death in the United States and poses a major
health and economic burden worldwide. While traditional treatments like surgery, chemotherapy,
radiation therapy, and hormone therapy have been successful and have decreased cancer
mortality, cancer incidence in all sites continues to rise. Consequently, there is an immediate
need to find new therapeutics for the treatment of cancer. In recent years, and with the continuing
push towards personalized medicine, cancer biomarkers have become crucial to detect, treat, and
monitor cancer. Thymidine kinase 1 (TK1) has been identified as a cancer biomarker with
diagnostic, prognostic, and therapeutic potential. TK1 is a nucleotide salvage pathway enzyme
responsible for maintaining a balance in the cell nucleotide pool and providing the cell with
thymidine monophosphate, which upon further phosphorylation is incorporated into DNA during
cell replication. TK1 has been found to be upregulated in the serum of cancer patients. Serum
TK1 (sTK1) has been used as an early diagnostic and prognostic biomarker in many types of
cancer and has been shown to be a better proliferation biomarker than Ki67.
In this dissertation, we described the characterization of TK1 as a cancer biomarker that
associates with the plasma membrane of hematological malignancies such as Burkitt’s
lymphoma, acute lymphoblastic leukemia, acute promyelocytic leukemia, acute T cell
lymphoma, and solid malignancies such as lung, breast, and colon cancer. We also describe the
different oligomeric TK1 forms that are found on the cell membrane and show that membrane
TK1 has activity. We assess the clinical relevance of TK1 in all these malignancies, looking at
tissue expression as well as gene expression from patients from The Cancer Genome Atlas
database. We find that TK1 is not expressed on the surface of normal cells, whether they are
proliferating or not, making TK1 a unique cancer biomarker, with the potential to be used in
targeted therapy. We also find that TK1 expressed on the surface may be involved in the
invasion potential of cancer cells. The knowledge gained from this study will help researchers
working in clinical research and cancer immunotherapeutics to potentially use TK1 as a
biomarker and cancer target, and thus providing another weapon against cancer.

Keywords: thymidine kinase 1, TK1, cancer biomarker
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CHAPTER 1: The Biology of Thymidine Kinase 1
Introduction
Cancer is a group of complex diseases that are characterized by unregulated cell
proliferation and cell death, tumor-promoting inflammation, genome instability and mutations,
induction of angiogenesis, evasion of the immune system, dysregulation of metabolic pathways,
immortal cell replication, and activation of metastasis and invasion.1 Despite efforts to improve
prevention methods, early detection, and treatments, cancer continues to be the second leading
cause of death in the United States and a major economic burden to both developed and
underdeveloped countries, indicating a critical need to identify clinically relevant cancer-specific
biomarkers.2 Thymidine kinase 1 (TK1) has been identified as a cancer biomarker that has
diagnostic, prognostic, and therapeutic potential.3,4
Cells undergoing normal proliferation must maintain a balanced supply of
deoxyribonucleotides to avoid replication stress, a common source of genome instability.5
Mammalian cells synthesize deoxyribonucleotide triphosphates (NTPs) either de novo or through
the nucleoside salvage pathway. TK1 belongs to the deoxyribonucleoside kinase family, a group
of four enzymes that catalyze the first phosphorylation step of deoxyribonucleosides in the
salvage pathway.6 TK1’s main function is to phosphorylate deoxythymidine to deoxythymidine
monophosphate (dTMP) using ATP as the phosphate source.3,7 Further phosphorylation of dTMP
yields deoxythymidine triphosphate (dTTP), which is then incorporated into DNA. While most
deooxyribunucleoside kinases are dimers, TK1 is unique because its most active form is a
tetramer (Figure 1-1).6
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Figure 1- 1. Structure of human thymidine kinase 1.
A) Monomer subunit structure of human TK1 with dTTP colored according to atom type. Mg2+ is shown in yellow,
and Zn2+ is shown in gray. B) Tetrameric structure of human TK1. Adapted from Welin M, Kosinska U, Mikkelsen
N-E, et al. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci U S A.
2004;101(52):17970-17975. doi:10.1073/pnas.0406332102.

There are two major enzymes responsible for maintaining the cellular nucleotide pool,
TK1 and dCK. TK1 is the only one whose expression is tightly regulated by the cell cycle.7
TK1’s levels are low or undetectable during G1 phase, rising during late G1 phages, peaking
during S phase, and again decreasing during the G2 phase.8 The increased levels of TK1 during
the S phase are due to a 3-fold increase in TK1 mRNA transcription and 12-fold increase in
translation efficiency of that mRNA.8 During the G2 phase, TK1 levels decrease as a result of a
C-terminal dependent degradation of the enzyme through the APC/C-Cdh-1 pathway.9 The other
salvage pathway enzyme responsible for maintaining the cellular nucleotide pool is
deoxycytidine kinase (dCK), which phosphorylates deocycytidine, deoxyadenoside and
deoxyguanosine.10 TK1 interacts with dCK, helping counteract dCK inactivation, which results
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in restoring dCTP, dATP, and dGTP levels. The interaction between dCK and TK1 demonstrates
the complex and redundant functions of TK1 (Figure 1-2).5

Figure 1- 2. TK1 protein-protein interaction network predicted by STRING.
Colored lines represented different interactions: black (co-expression), pink (experimental), green (text mining),
blue (homology).

Studies have also shown that TK1 is involved in DNA repair. Chen et al. (2010) showed
that p53-/- tumor cells upregulate TK1 as a response to DNA damage.7 Other groups have shown
that p53 is essential for TK1 controlled expression and upon loss of p53, TK1 levels increase.11–
13

This increase of TK1 seems to be essential for tumor cells seeking DNA repair. McKenna et

al. showed that increased TK1 levels and increased dTTP levels are necessary for DNA repair in
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tumor cells following treatment with radiation.14 Thus, TK1 functions as a mechanism of
resistance for the survival of cancer cells.3
TK1 has been widely studied as a cancer serum biomarker. TK1 has been found
upregulated in the serum and in tissues of cancer patients. Serum TK1 (sTK1) can be used as
early detection and diagnostic biomarker because the presence of TK1 in serum results from
tumor cell death and correlates with tumor size.15–17 Higher serum TK1 concentration levels
correlate with a more advance stage and grade in many cancer types.14,18–20 Moreover, sTK1
levels show prognostic potential and can help predict relapse after primary diagnosis in both
solid and hematological malignancies.21–25
Summary of research chapters
Chapter 2 outlines our efforts to characterize TK1 as a cancer biomarker and its clinical
relevance in multiple hematological malignancies including Burkitt’s lymphoma (Raji), acute
promyelocytic leukemia (HL60), and acute T cell leukemia (Jurkat) cell lines, and acute
lymphoblastic lymphoma (ALL) clinical samples. We show that TK1 localizes on the cell
membrane of malignant cells and is absent on the membrane of normal resting and normal
proliferating lymphocytes, suggesting that TK1’s membrane localization is independent from
proliferation. These findings were confirmed through flow cytometry, confocal microscopy, and
scanning electron microscopy. We also show that membrane TK1 is found in monomeric and
dimeric forms. Moreover, we show that TK1 isolated from the membrane has enzymatic activity,
suggesting a function for TK1 on the membrane.
In Chapter 3, we characterize TK1’s potential as a tumor biomarker and
immunotherapeutic target and clinical relevance in the major cancer killers: lung, breast, and
colorectal cancers. We showed that TK1 localizes on the membrane of lung (NCI-H460, A549),
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breast (MDA-MB-231, MCF7), and colorectal (HT-29, SW620) cancer cell lines. We also
compared TK1 expression levels in normal and malignant tissue through flow cytometry and
immunohistochemistry, showing that TK1 is upregulated exclusively in malignant cells,
independently of proliferation. We also analyzed in-silico RNA-Seq patient data from The
Cancer Genome Atlas (TCGA), where we show differential expression of the TK1 gene in lung,
breast, and colorectal cancer patients. We also show that TK1 is expressed in both HER2+ and
triple negative breast cancer, suggesting that TK1 is a membrane biomarker in hormoneindependent breast cancer. We also show that as breast cancer progresses, TK1 levels positively
correlate with epithelial-mesenchymal transition (EMT). This suggests that TK1 may have a role
in invasion and metastasis in breast cancer. These results suggest TK1’s relevance as a potential
immunotherapeutic target.
In Chapter 4, we explore the role of TK1 on the membrane. Using siRNA, we silenced
TK1 expression on the membrane of A549 cells, a lung cancer cell line known to express TK1
on its membrane. We show that TK1 membrane expression is significantly downregulated after
60 hours post-transfection. Using a Matrigel-based quantitative invasion assay, we measured cell
invasion potential in cells either expressing or lacking TK1 on their membrane. We found that
cells that lack TK1 on their membrane exhibit a significantly decreased invasion potential
compared to cells expressing TK1. These results suggest that TK1’s presence on the membrane
may play a role in invasion and cell migration in cancer.
Chapter 5 is a review paper where we describe macrophage polarization and its role in
cancer. We define macrophage polarizations M1 and M2 and their subsets, their functions and
gene expression, and what molecules induce polarization to their respective subsets, as well as
their activation pathways and metabolism. We also describe tumor associated macrophages
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(TAMs) and their role in the cancer microenvironment and potential approaches to cancer
immunotherapy using macrophages.
Summary of appendices
Appendix 1 contains data that accompanies a published abstract in Cancer Research
entitled “How does the tumor microenvironment affect macrophage aggressiveness?” In this
study, we show that U937-derived macrophages decrease their phagocytic capacity when
exposed to cells and conditioned media from breast, lung, colon, and Burkitt’s lymphoma cell
lines. We also observed that these U937-derived macrophages show an M2-like gene expression
profile, upregulating IL-10 and downregulating IL-12.
Appendix 2 contains data that accompanies a published abstract in Cancer Research
entitled “Prostate cancer exosomes and their effects on macrophage engulfment and
polarization.” In this study, we researched the effects of prostate cancer-derived exosomes on
macrophage engulfment and polarization. We found that phagocytosis was affected around 5
hours post-exposure to exosomes. Macrophage gene expression macrophages exposed to
exosomes change around 4 hours, where we see an upregulation of IL-10 and downregulation of
IL-12, mimicking a M2 macrophage polarization.
Appendix 3 contains unpublished data from a study done on the role of antioxidants in
cell response against oxidative stress and reactive oxidative species (ROS). The abstract from
this study was published in Cancer Research as “Differences in cellular antioxidant activity in
Burkitt's lymphoma and normal human lymphocytes.” We explored the cellular antioxidant
capacity in normal lymphocytes and Raji cells before and after exposure to a radical oxygen
initiator followed by exposure to L-Ascorbic, resveratrol, α-Tocopherol, glutathione, and αLipoic acid for 10, 20, 45, and 60 minutes. Our study shows that cancer cells cannot maintain
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balance after oxidative stress, as we see that they increase and keep increasing antioxidant
capacity over time. Normal cells stop increasing their antioxidant capacity when they sense that
the oxidative stress has been reduced. Our study also shows that the differences we see between
Raji cells and normal lymphocytes with this oxidative treatment may suggest that cancer cells
can increase their antioxidant capacity when they are exposed to oxidative stress, a mechanism
that may be employed to protect themselves from the damaging effects of chemotherapy drugs.
Appendix 4 contains data from a yeast-2-hybrid assay where we evaluate protein-protein
interactions using a human cDNA library in a prey plasmid and the TK1 gene in a bait plasmid.
We report 4 novel proteins that interact with TK1.
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CHAPTER 2: Biomarker Analysis and Clinical Relevance of Thymidine Kinase 1 on the Cell
Membrane of Burkitt’s Lymphoma and Acute Lymphoblastic Leukemia

The following chapter is taken from an article published in OncoTargets and Therapy Journal.
All content and figures have been formatted for this dissertation but it is otherwise unchanged.

Abstract
Thymidine kinase 1 (TK1) is an enzyme involved in DNA synthesis and repair. TK1 is
elevated in cancer patients’ serum, making it a useful tumor proliferation biomarker that strongly
correlates with cancer stage, metastatic capabilities, and recurrence risk. In this study, we show
TK1 is upregulated and localizes on the plasma membrane of Burkitt’s lymphoma, acute
lymphoblastic leukemia (ALL), and other hematological malignancies. Using flow cytometry,
we confirmed that TK1 localizes on the surface of Raji, HL60, Jurkat cell lines, and on ALL
clinical samples. Using fluorescent microscopy, we found a strong association of TK1 with the
plasma membrane in Raji, HL60, and Jurkat cell lines. These findings were also confirmed by
electron microscopy. Also, our study demonstrates this phenomenon does not occur on normal
resting or proliferating lymphocytes. Interestingly, membrane TK1 is found in all oligomeric
forms ranging from monomer to tetramer and exhibit enzymatic activity. These findings suggest
TK1as a possible target for immunotherapy with the potential to be utilized in the treatment of
hematological cancers.
Introduction
Thymidine kinase 1 (TK1) is a nucleotide salvage pathway enzyme primarily responsible
for phosphorylating deoxythymidine to deoxythymidine monophosphate.7 Under normal
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conditions, TK1 is tightly regulated by the cell cycle. Usually, TK1 levels are low in G1, peak in
S phase, and low during late G2/M phase.8 The low levels of TK1 during the late G2/M phase
occur because degradation, which is thought to be regulated by polyubiquitination that targets
degradation via the APC/C pathway.3 The rapid increase in TK1 levels during S phase is thought
to be partly mediated by a TK1 regulatory switch, which happens when TK1 switches from a
dimer (inactive enzyme) to a tetramer (active enzyme).3,26,27
In cancer events and upon loss of p53 regulation, TK1’s cell cycle regulation is lost and
TK1 levels are upregulated.12 TK1 has been found upregulated in tissue and serum in both solid
tumors and hematological malignances, which is why TK1 has been extensively studied as a
cancer proliferation biomarker.15,17 The diagnostic and prognostic potential of TK1 has been
demonstrated using the traditional TK activity radioassay for hematological malignancies and
solid tumors.26,28 Moreover, TK1 levels in serum have been shown to have diagnostic potential in
other cancers such as bladder, cervical carcinoma, gastric, non-small cell lung, renal and
colorectal cancers.14,18,21,22,24,28–30 Early events in carcinogenesis show an upregulation of TK1 in
the serum as well so TK1 has also been studied as a prognostic marker in many cancer
types.15,17,20,31 In summary, high TK1 serum levels correlate with tumor aggressiveness and can
be indicative of early events in carcinogenesis.15,28
Burkitt’s lymphoma (BL) and acute lymphoblastic leukemia (ALL) are some of the most
highly proliferative hematological malignancies and primarily affect children, with a small
incidence in adults too.32,33 BL is an aggressive non-Hodgkin lymphoma that affects B cells. BL
is the most common type of pediatric cancer in malaria-endemic regions, such as equatorial
Africa, Brazil, and Papua New Guinea, affecting over 40 million children every year.34 While the
current available multi-agent chemotherapy treatment (cyclophosphamide, vincristine,
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prednisolone, and doxorubicin) has a 5-year event-free survival rate of over 90% in high-income
countries, the survival rate is much lower in low-income countries (50% for 1-year event-free
survival rate).35,36 ALL is the most common hematological malignancy diagnosed in children in
the United States with over 6000 cases every year.37,38 The highest peak of incidence occurs
between the ages of 3-9 years and it is the number one cause of death from cancer in people
under 20 years old.37,38 One of the major complications with ALL in children is the infiltration of
leukemic cells in the central nervous system (CNS), which usually occurs in relapse. In the past
few decades, there has been major improvements in ALL treatments including an intensive 8week chemotherapy regimen that has increased ALL 5 year-remission rates to up to 85% and
overall survival rates from 10% to 90%.39 These new treatments include a combination
chemotherapy regimen during the 6-8 months after remission designed to prevent relapse and
CNS leukemic infiltration. Unfortunately, 15-20% of children with ALL will relapse and their
survival rates drop to 20-30%.37 More research is needed to understand the unique characteristics
of BL and ALL and to find new targets that could help increase survival.
Due to the proliferative nature of BL and ALL, we hypothesized that TK1 was highly
expressed in BL and ALL cells. While researching this hypothesis, we found TK1 to be
overexpressed on the membrane of BL, acute promyelocytic leukemia, acute T cell leukemia,
and ALL clinical samples. Of note, TK1 is not readily detectable on the membrane of normal
resting or proliferating lymphocytes, and thus TK1 membrane localization appears to be an event
exclusive in malignant cells. Moreover, membrane TK1 is found in all oligomeric forms and
exhibits enzymatic activity. These findings suggest TK1 is a tumor specific antigen on the cell
surface and therefore a potential immunotherapy target for BL and ALL.
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Materials and Methods
Tissue collection, cell lines, and ALL samples
Raji (Burkitt’s lymphoma), HL60 (acute promyelocytic leukemia), and Jurkat (acute T
cell leukemia) cell lines were purchased from ATCC (Manassas, VA). All cell lines were
authenticated by short tandem repeat (STR) analysis at the University of Arizona Genetics Core
Facility prior to our study. All cells were grown in RPMI 1640 supplemented with 10% FBS and
2mM L-glutamine and incubated at 37°C with 5% CO2. ALL samples were obtained from
patients at diagnosis or relapse after informed consent on a biobank protocol at the Huntsman
Cancer Institute (Salt Lake City, UT) and frozen with DMSO and albumin in aliquots. ALL
samples were thawed at 37ºC and washed with Dulbecco's phosphate-buffered saline (DPBS)
immediately before use.
Mononuclear cell separation
Whole blood was collected from healthy young volunteers ages 18-30 under IRB
approval from the Office of Research and Creative Activities at Brigham Young University
(BYU X090281). All healthy blood volunteers provided informed consent. Blood was diluted 1:1
with DPBS layered on top of Lymphocyte Separation Medium (LSM) (Cellgro, Corning Life
Sciences, VWR International, Radnor, PA) and centrifuged at 400 x g for 30 mins without brake
or acceleration. The mononuclear cell layer was aspirated and rinsed with DPBS. The cells were
treated with red blood cell lysis buffer and resuspended in RPMI 1640 supplemented with 10%
FBS and 20% human serum from the original blood donor. After a further incubation for 24
hours at 37°C with 5% CO2, the lymphocytes were aspirated and washed with DPBS and
prepared for flow cytometry and scanning electron microscopy.
B cell magnetic sorting
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Lymphocytes (B and T cells) were obtained by mononuclear cell separation from whole
blood with LSM. Cells were then washed with MACS buffer and stained with anti-CD19
antibody conjugated to biotin. We incubated these cells with streptavidin-gold magnetic MACS
beads (Miltenyi Biotech) and CD19+ cells were sorted via magnetic selection. Cells were
resuspended in MACS buffer and then washed and resuspended in DPBS for downstream
application.
B cell proliferation
B cells obtained through magnetic selection were seeded at 2x105 cells/mL in a 6 well
plate in RPMI 1640 supplemented with 10% FBS. We used the CellXVivo Human B Cell
Expansion Kit (R&D Systems) to induce proliferation. We counted the B cells and incubated
them following the kit’s instructions for 5 days. After 5 days, we observed the cells under a
microscope to assess proliferation and counted them again to quantify division. Cells were
washed and resuspended in DPBS and used in flow cytometry.
Antibodies
We used 3 custom mouse monoclonal antibodies developed in our lab against TK1 (CB1,
A72, and A74) and a commercially available rabbit monoclonal antibody against TK1 (ab91651)
(Abcam). CB1 binds to a region in the C-terminal domain of TK1, specifically to the active
domain.40–42 A72 and A74 are against an immunodominant region besides the TK1 C-terminal
domain.28 The three custom antibodies were conjugated to FITC using a conjugation kit
(EasyLink, Abcam, ab102884) and stored in the dark at 4°C. The custom antibodies were used
for most assays and the commercially available antibody (Commercial) was used for
immunohistochemistry. The ALL samples were stained with CD34-APC-Cy7, HLA-DR-
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AlexaFluor488, and Commercial-APC for staining of ALL samples. CD34 and HLA-DR
antibodies were purchased from BioLegend (San Diego, CA).
Flow cytometry
Raji, Jurkat, HL60, normal lymphocytes, and B cells were washed 3X in DPBS. All cells
were resuspended in DPBS at 5x105 cells/mL and were placed in individual microcentrifuge
tubes and incubated with Fc block (Human TruStain FcX, BioLegend, San Diego, CA) for 10
minutes at room temperature. Cells were then stained with CB1, A72, and A74 conjugated to
FITC. Negative controls include unstained cells and cells stained with an isotype antibody. ALL
samples were resuspended in Cell Staining Buffer (BioLegend, San Diego, CA), incubated with
Fc Block for 10 minutes at room temperature and then stained with isotype control, CD34 (APCCy7), HLA-DR (AlexaFluor488) to confirm ALL phenotype and with Commercial (APC) to
check for TK1 expression. For lymphocytes treated with TK1, we incubated 5x106 cells per well
in a 6-well plate and added DPBS or concentrations of yeast recombinant TK1 at 0.25uM, 0.5uM
or 0.75uM. Cells were incubated at 37ºC and 5% CO2 for 24 hours, then the cells were washed
3X in DPBS and incubated in Fc block for 10 minutes, after which cells were stained with antiTK1 antibody ab91651 and then with an anti-rabbit secondary FITC antibody. Negative controls
include unstained sample, (rabbit) anti-NFKB, and anti-rabbit secondary FITC antibody. We also
performed dead cell discrimination using a PI solution (2mg/mL) immediately before analysis.
We collected 10x104 events per sample in a flow cytometer (Attune, Life Technologies) and data
was analyzed using the FlowJo software (FlowJo, Inc., Ashland, OR).
Fluorescent microscopy
Raji, HL60, Jurkat, and normal lymphocytes were stained with FITC-conjugated
antibodies, namely isotype control, anti-NaK antibody, or anti-TK1 antibody (CB1) for 30
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minutes on ice and in the dark. Cells were washed with cold DPBS and then were resuspended at
5x105 cells/mL. 20uL of cell solution were placed on a glass slide, after which a drop of
mounting medium containing DAPI was added to the sample (Vectashield Antifade Mounting
Medium with DAPI, Vectashield, Burlingame, CA), and a coverslip was placed on top. Cells
were visualized in a light microscope (Zeiss Imager A.1 Fluorescence Microscope, Carl Zeiss,
Oberkochen, Germany) using different channels to detect fluorescence. Blue represents DAPI
fluorescence and green represents FITC fluorescence.
Scanning electron microscopy
Raji and normal lymphocytes were washed 3X in DPBS for 5 minutes to remove medium
and cellular debris. The cells were then resuspended in flow cytometry staining buffer
(eBioscience) for 15 minutes and then blocked with 1% Bovine serum albumin (BSA) in DPBS
(BSA/DPBS) for 5 minutes. We then added anti-TK1 antibody (A72) conjugated to biotin at a
concentration of 0.005ug/uL and incubated the cells for 15 mins on ice. After incubation with
primary antibody, we washed the cells with BSA/DPBS twice. We then stained the cells with
anti-biotin conjugated to 2nm gold nanoparticles (Nanoprobes, Yaphank, NY) at a concentration
of 1:500 in BSA/DPBS and incubated for 30 minutes on ice. We then washed the cells with
BSA/DPBS for 5 minutes and twice with DPBS to remove any block. After staining, we fixed
the cells in 0.2 % glutaraldehyde for 15 minutes followed by a wash in 0.02M glycine for 10
minutes to quench the fixative. We then rinsed the cells 3X in DPBS and used a Cytocentrifuge
(Cytospin, Thermo Scientific, Waltham, MA) to spread the cells onto coverslips. Cells were then
rinsed 3X with ddH2O and gold particles, if present, were enhanced for 3 minutes using the
GoldEnhance™ EM Plus kit (Nanoprobes). The cells were then rinsed 3X with ddH2O and
dehydrated via sequential washes of 70%, 80%, 90%, and 100% EtOH for 5 min each. After the
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coverslips were dry, we imaged them using an XL-30 ESEM (Philips, Amsterdam, Netherlands).
Pictures provided were taken using a GSE detector. Raw images are provided next to enhanced
images showing red dots as gold. Energy Dispersive Analysis X-ray (EDAX) was performed on
all samples to quantify the levels of gold present. EDAX analysis will provide a k-ratio, a Z
value, an A value, and an F value. The k-ratio represents the element’s peak height compared to
a sample of the pure element collected under the same conditions. The Z value represents a
correction in the atomic number taking backscattered election yield of the pure element and the
sample. The A value represents a compensation for X-rays generated in the sample that are
cannot emit energy. The F value represents a correction for the generation of X-rays. We used
these EDAX output values to normalize our samples gold weight percentages using the
following equation:

𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 =

𝑘𝑘 − 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 ∗ 100
𝑍𝑍 ∗ 𝐴𝐴 ∗ 𝐹𝐹

Plasma membrane and cytoplasmic protein isolation and Western blotting
To separate the plasma membrane and cytoplasmic proteins, we used the Pierce™ Cell
Surface Protein Isolation Kit (Thermo Fisher Scientific, Waltham, MA, Cat # 89881). For this
procedure, we used 4x107 Raji cells or normal lymphocytes per test. Normal lymphocytes were
isolated as described in the “Mononuclear cell separation” section. To label the cells with biotin,
cells were incubated with a 40 mL of biotin solution in a T75 flask. Biotin solution was made by
dissolving the contents of one vial of Sulfo-NHS-SS_Biotin (provided in the kit) in 48mL of icecold PBS. The flask was incubated on a rocking platform with gentle agitation for 30 mins at
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4°C. After incubation, 500uL of quenching solution were added to the flask to quench the
reaction. Then, cells were transferred to a conical tube and pelleted at 500 x g for 3 minutes, after
which the supernatant was discarded. Cells were then washed with 5mL of TBS by pipetting up
and down twice with a serological pipette and pelleted at 500 x g for 3 minutes. A cocktail of
protease inhibitors was added to 500uL of lysis buffer (provided in the kit) and added to the cell
pellet. The cells in lysis buffer were transferred to a microcentrifuge tube and resuspended in the
fluid by pipetting up and down. The cells were then disrupted using a cell disruptor (Sonicator
3000, Misonix, Inc., Farmingdale, NY) at low power (1.5) on ice using five 1-second bursts.
Cells were incubated for 30 minutes on ice, vortexed every 5 minutes for 5 seconds, and
sonicated for 1 second at low power (1.5) every 10 minutes. The cell lysate was centrifuged at
10,000 x g for 2 minutes at 4°C and the clarified supernatant transferred to a new
microcentrifuge tube. To isolate the biotin-labeled proteins, the clarified supernatant was added
to a column that contained 500uL of NeutrAvidin Agarose that had been previously washed with
500uL of wash buffer and centrifuged for 1 minute at 1000 x g. The column was capped and
incubated for 60 minutes at room temperature with end-over-end mixing using a rotator. Then,
the column was centrifuged for 1 minute at 1000 x g and the flow-through kept for cytoplasmic
protein analysis. The column was washed 3 times with 500uL of wash buffer containing a
cocktail of protein inhibitors to remove any other cytoplasmic proteins. To elute the membrane
proteins, a 50mM DTT solution was made by adding 23.7uL of 1M DTT to 450uL SDS-PAGE
sample buffer. 450uL of DTT solution were added to the column and incubated for 60 minutes at
room temperature with an end-over-end mixing on a rotator. The column was then centrifuged
for 2 minutes at 100 x g and the flow-through collected and stored at -20°C. For Western blot
analysis, samples were thawed on ice after which they were boiled for 5 minutes and then run on
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a 12% acrylamide SDS gel at 90 V for 2-3 hours. The proteins on the gel were transferred onto a
nitrocellulose membrane at 90 V for 50 minutes. The membrane was blocked with 5% non-fat
milk in DPBS for 1 hour at 4°C in a rotating platform and then incubated in anti-TK1
commercial antibody (ab91651) in a 1:1000 dilution in milk overnight at 4°C in a rotating
platform. Membrane was washed 3 times in DPBS for 3 minutes each in a rotating platform and
then incubated with a IRDye 800 donkey anti-rabbit secondary antibody for 1 hour at 4°C in a
rotating platform (LI-COR, Lincoln, NE). Finally, the membrane was washed 3 times with
DPBS and imaged in an Odyssey CLx Imaging System (LI-COR, Lincoln, NE).
Membrane separation and TK1 activity radioisotype assay
Plasma membranes were separated using a sucrose gradient. First, Raji, Jurkat, and HL60
cell line were grown to an exponential growth phase. 17x107 cells were pelleted at 210 x g for 20
minutes and the pellets were resuspended in 6mL of a buffer consisting on 20% (v/w) sucroseTris buffer (pH 6.8). The cell suspension was freeze-thawed in liquid nitrogen and then at 37°C
3X and centrifuged at 600 x g for 10 mins at 4°C to collect cell membranes. The supernatant was
discarded and the pellet, containing the membranes, was washed with Tris buffer (pH 6.8) and
then resuspended in 9mL of 20% (w/v) sucrose-Tris buffer. A two-step sucrose gradient was
prepared in a Beckman open-top tube (Beckman Coulter, Brea, CA, catalog number 337922) by
adding 13 mL of 70% (w/v) sucrose-Tris buffer, followed by 12 mL of 50% (w/v) sucrose-Tris
buffer, followed by 9mL of 20% (w/v) sucrose-Tris buffer containing the membranes. The
gradients were centrifuged at 25,000 rpm for 14 hours in a Beckman L8-60M ultracentrifuge
(Beckman Coulter, Brea, CA). The plasma membranes are found at the 50-70% (w/v) sucroseTris buffer interface. The membranes were collected by the bottom drip method, which consists
on using a hot needle to create a hole at the bottom of the tube and collect each layer separately
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drop-by-drop. The 50-70% (w/v) sucrose-Tris buffer interface was diluted to below 20% (w/v)
sucrose-Tris buffer using Tris buffer (pH 6.8). The diluted interface was centrifuged at 47,000
rpm for 1hr and the pellet resuspended in 1mL Tris buffer (pH 6.8). This solution containing the
membranes was used in the TK radioisotype assay. The TK radioisotype assay was previously
described by O’Neill et al was performed.43 Briefly, reactions were set up with 100 uL of the
solution containing the membranes and 100 uL of a solution containing 2 μM [3H]-Thymidine,
0.02 M Tris, 20 uM MgCl2, 0.2 M KCl, 0.1 M NH4Cl, 5 mM β-mercaptoethanol or dithiothreitol
(DTT), and 4 mM ATP or 4 mM CTP for 1 hr at 37°C. After incubation, four 25 uL of each
sample were applied to 2.5 cm DE-81 paper discs (Sigma-Aldrich, St. Louis, MO, catalog #
Whatman Article No., 28419431) and the discs were washed 3X in 20mM ammonium formate
(Sigma- Aldrich, St. Louis, MO, catalog # 156264), followed by a wash in 95% ethanol and a
wash in distilled water. The discs were placed in scintillation vials with 3m of CytoScint (MP
Biomedicals, Santa Ana, CA, catalog # 0188245301) and radioactivity was measured using a wet
scintillation counter (Beckman Coulter, Brea, CA, model number LS6500).
Statistical analysis
Flow cytometry and TK1 activity data were analyzed using an unpaired t-test comparing
the isotype control to each of the samples. Error bars represent the standard error of the mean.
EDAX data were analyzed using a Kruskal-Wallis One-way ANOVA test. 2-tailed P-values
≤0.05 were determined to be significant.
Results
Flow cytometry shows a significant fluorescent shift in Raji, HL60, and Jurkat cells bound to
anti-TK1 antibodies suggesting TK1 is localized on the plasma membrane of these cells
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Using standard surface staining and flow cytometry, we discovered that Raji cells have a
significant fluorescent shift compared to controls when bound to TK1 antibodies, suggesting
TK1 is found on the outer cell membrane of Raji cells (Figure 2-1 A-C). We used an anti- NF-κB
antibody as a control to confirm the integrity of the cell membrane since TK1 is also a
cytoplasmic protein. The cells were NF-κB negative, which suggests our anti-TK1 antibodies
were indeed bound to the surface of the cell and not internalized. (Figure 2-1 A). We also used a
CD19 as positive surface staining control. This finding that TK1 is on the surface of Raji cells
was confirmed using three different monoclonal antibodies against different TK1 epitopes
(Figure 2-1 B). Quantification and statistical analysis of the fluorescent shifts show a significant
difference in the percentage of Raji cells positive for TK1 compared to isotype control (Figure 21 C).
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Figure 2- 1. Flow cytometry quantification analysis of normal lymphocytes.
A) Lymphocytes were isolated from whole blood and stained with anti-TK1 antibodies A72, A74, and CB1, antiCD45 (positive control), isotype control, and anti-NFkB antibodies. Lymphocytes were also stimulated to proliferate
and then stained with anti-TK1 antibodies A72, A74, and CB1, anti-CD45 (positive control), isotype control, and
anti-NFkB antibodies. Normal resting lymphocytes show absence of TK1 on their surface even under proliferating
conditions. B) Lymphocytes were treated with supraphysiological levels of purified TK1 (0.25uM, 0.5uM, and
0.75uM TK1). Lymphocytes were stained with anti-TK1 antibody (ab91651) and CD52 (positive control).
Lymphocytes show non-significant amounts of TK1 on their surface, suggesting that extracellular sources of TK1
don’t interact with the membrane. P-value ≤0.001= ***, P-value ≤0.0001= ****.
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To confirm these findings, we also stained other hematological cancer cell lines such as
HL60 (acute promyelocytic leukemia) and Jurkat (acute T cell leukemia) with CB1 conjugated to
FITC and a commercially available anti-TK1 antibody conjugated to FITC. We used CD45 and
Na+/K+ ATPase as positive controls, as both cells express them highly on their membrane. Both
HL60 and Jurkat cells showed a significant fluorescent shift when bound to TK1 antibody
(Figure 2-2).

Figure 2- 2. Flow cytometry analysis of HL60 and Jurkat cells.
Here we show the quantification of the percentage of cells showing a positive fluorescent shift when bound to
conjugated antibodies. The percentage of HL60 cells that are positive for TK1 (CB1 and commercially available
anti- TK1 antibodies) is similar to that of CD45 and Na+K+ ATPase (positive controls) and significantly higher than
the isotype control. Similarly, Jurkat cells show a significantly higher percentage of TK1+ cells than isotype controls
with both CB1 and commercially available anti-TK1 antibodies. P-value ≤0.05= *, P-value ≤0.01= **, P-value
≤0.001= ***.
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Fluorescent microscopy suggests TK1 is associated with the plasma membrane
To confirm that TK1 was associated with the membrane, we produced images using a
fluorescent microscope to visualize this membrane localization phenomenon. We stained Raji,
Jurkat, HL60, and normal lymphocytes with CB1 antibody conjugated to FITC (Figure 2-3). Our
isotype control shows minimal fluorescent background while the samples treated with antibodies
against Na+K+ ATPase and TK1 showed strong FITC signals on the cell membranes, suggesting
a strong association of TK1 with the cell membranes. Normal lymphocytes show minimal FITC
signal associated with TK1, indicating minimal presence of TK1 on their surface.

DAPI

AntiIsotype IgG Na+/K+ ATPase

Anti-TK1

Raji cells

Jurkat cells

HL60 cells
Normal
lymphocytes
Figure 2- 3. Fluorescent microscopy images of viable Raji, Jurkat, HL-60, and normal lymphocytes cells stained
with CB1-FITC (anti-TK1 antibody), isotype control, anti-Na+K+ ATPase antibody, and DAPI at 20X.
Hematological cell lines stain positive for TK1 and Na+K+ ATPase. Normal lymphocytes do not stain positive for
TK1. All cells are negative for isotype control. We can observe an association of the fluorescence of FITC with the
membrane. These images suggest TK1 associates and localizes on the cell membrane.
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TK1 is absent on the plasma membrane of normal lymphocytes
To test whether TK1 membrane localization was exclusive to malignant cells, we stained
normal resting lymphocytes from whole blood with our antibodies. We isolated mononuclear
cells from whole blood using Lymphocyte Separation Medium. We analyzed these cells
immediately using flow cytometry. These normal lymphocytes were CD45+ and TK1-. We also
tested whether the localization of TK1 on the surface was due to proliferation. We magnetically
sorted CD19+ cells from mononuclear lymphocytes isolated from whole blood by using an antiCD19 antibody conjugated to biotin which we bound to streptavidin-magnetic beads. We
stimulated these cells to proliferate using the CellXVivo Human B Cell Expansion Kit (R&D
Systems). We then stained the cells with the same antibodies used with the resting lymphocytes
using CD45 as positive control and analyzed the cells through flow cytometry. Flow cytometry
analysis confirmed that normal lymphocytes do not significantly upregulate TK1 on their surface
even when undergoing cell division (Figure 2- 4 A). These results indicate that the localization of
TK1 on the outside layer of the plasma membrane may be an event exclusive to malignant cells.
Additionally, to test whether extracellular TK1 interacts with membrane, we incubated
normal lymphocytes with 0.25uM, 0.50uM, 0.75uM, and 1uM of purified TK1 for 24 hours and
then probed the cells with anti-TK1 antibody. Flow cytometry analysis showed that there is no
significant expression of TK1 on the surface of these lymphocytes when exposed to
supraphysiological levels of TK1 (Figure 2-4 B). These results suggest that there is no
interaction of membrane with extracellular TK1.
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Figure 2- 4. Flow cytometry quantification analysis of normal lymphocytes.
A) Lymphocytes were isolated from whole blood and stained with anti-TK1 antibodies A72, A74, and CB1, antiCD45 (positive control), isotype control, and anti-NFkB antibodies. Lymphocytes were also stimulated to proliferate
and then stained with anti-TK1 antibodies A72, A74, and CB1, anti-CD45 (positive control), isotype control, and
anti-NFkB antibodies. Normal resting lymphocytes show absence of TK1 on their surface even under proliferating
conditions. B) Lymphocytes were treated with supraphysiological levels of purified TK1 (0.25uM, 0.5uM, and
0.75uM TK1). Lymphocytes were stained with anti-TK1 antibody (ab91651) and CD52 (positive control).
Lymphocytes show non-significant amounts of TK1 on their surface, suggesting that extracellular sources of TK1
don’t interact with the membrane. P-value ≤0.001= ***, P-value ≤0.0001= ****.
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Scanning Electron Microscopy (SEM) shows further confirmation of TK1 localization on the
surface of cancer cells
To further confirm the location of TK1 on the surface of cancer cells, we developed a
scanning electron microscopy (SEM) protocol and used gold nanoparticles to visualize TK1. For
this procedure, we used our A72 antibody. TK1 is shown to be expressed on the surface of Raji
cells (Figure 2-5 A-B) and is absent in normal resting lymphocytes (Figure 2-6 A-B). EDAX
analysis helped us quantify the amounts of gold present on the cell surface. The Raji cells probed
with A72 antibody show significantly higher amounts of gold bound to their membrane than Raji
cells probed isotype control. Raji cells probed with A72 antibody show similar amounts of gold
to Raji cells probed with Na+/K+ antibody (Figure 2-5 C). In normal lymphocytes, the amounts of
gold in Raji cells probed with A72 are similar to those probed with isotype control, suggesting
TK1 is absent on the surface of normal lymphocytes (Figure 2-6 C).

25

C

Figure 2- 5. Scanning Electron Microscopy of Raji cells.
A) Cells were stained with anti-biotin gold, anti-NFkB-biotin + anti-biotin gold, and anti-TK1 (A72)-biotin + antibiotin gold visualized through a GSE detector. White spots represent gold bound to the membrane of the cells. B)
Images were filtered so the white spots (gold) could be shown in red for better visualization. C) EDAX analysis
quantification of gold weight percentages in Raji cells stained with anti-biotin gold, anti-NFkB-biotin + anti-biotin
gold, A72-biotin + anti-biotin gold, and a positive control Na+/K+ ATPase-biotin + anti-biotin gold. The amount of
gold particles found on the surface of Raji cells when stained with anti-TK1 A72 antibody are significantly higher
than background. P-value ≤0.05= *, P-value ≤0.01= **.
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Figure 2- 6. Scanning Electron Microscopy of normal lymphocytes.
A) Cells were stained with anti-biotin gold, anti-NFkB-biotin + anti-biotin gold, and anti-TK1 (A72)-biotin + antibiotin gold visualized through a GSE detector. White spots represent gold bound to the membrane of the cells. B)
Images were filtered so the white spots (gold) could be represented in red for better visualization. No gold is can be
visualized in these samples. C) EDAX analysis quantification of gold weight percentages in normal lymphocytes
stained with anti-biotin gold, anti-NFkB-biotin + anti-biotin gold, A72-biotin + anti-biotin gold, and a positive
control Na+/K+ ATPase-biotin + anti-biotin gold. The amount of gold particles found on the surface of normal
lymphocytes when stained with anti-TK1 A72 antibody are the same as the background indicating the absence of
TK1 in these cells. P-value ≤0.0001= ****.
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ALL clinical samples also express TK1 on their plasma membrane
To ensure TK1’s relevance in clinical samples, we tested ALL samples (n=9) obtained
from the Huntsman Cancer Institute. These samples were CD34+ and HLA-DR+ as expected
(Figure 2-7 A). We performed alive/dead cell discrimination to prevent any false positives in
these samples. All ALL samples tested were positive for TK1. Cell viability impacted the
analysis as we got lower event counts when we discriminated dead cells. However, even in
samples with low viable cell count TK1 was expressed on the cell membrane. Percentage of cells
positive for TK1 varied from 8% to 43.5%, averaging 28.01% (Figure 2-7 B). We believe we see
this big range due to disease progression and grade.

A

B

Figure 2- 7. Flow cytometry analysis of ALL clinical samples.
A) Density plots of flow cytometry controls used in the analysis of ALL samples. Cells are CD45+ and HLA-DR+.
Controls indicate an insignificant fluorescent shift in cells stained with isotype IgG control and anti-NFkB antibody.
Cells appear to shift in fluorescence when bound to anti-TK1 antibody. B) Quantification of cells shifting towards a
greater fluorescence in ALL samples. ALL samples have a significant percent of cells with a greater fluorescent
shift compared to controls. P-value ≤0.01= **.
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TK1 on the membrane is found in different oligomeric
To further characterize TK1 on the membrane, plasma membrane and cytoplasmic
proteins were isolated from Raji cells and normal lymphocytes. Both the membrane and the
cytosolic proteins were run on a 12% acrylamide SDS gel and then transferred to a nitrocellulose
membrane and probed with anti-TK1 antibody ab91651. Results show that the Raji cell
membrane protein fraction contains mostly monomers and dimers of TK1 (Figure 2-8 A). On the
other hand, the normal lymphocyte membrane protein fraction contains minimal traces of TK1
(Figure 2-8 B).
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Figure 2- 8. Western blot of membrane and cytosolic fractions in Raji cells and normal lymphocytes and blotted
with anti-TK1 antibody.
A) Membrane proteins on viable Raji cells membranes were biotinylated or not (control) and then bound to
streptavidin beads. Membrane proteins bound to the beads were eluted and used as samples in a Western blot.
Samples were probed against TK1. We observe that TK1 found on Raji cells’ membranes adopts many oligomeric
forms as pointed by the arrows. B) Membrane proteins on viable normal lymphocytes were biotinylated or not
(control) and then bound to streptavidin beads. Membrane proteins bound to the beads were eluted and used as
samples in a Western blot. Samples were probed against TK1. We observe that normal lymphocytes do not show
any detectable TK1 on their membrane fraction.
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TK1 on the membrane shows activity
Membrane fractions of Raji, Jurkat, and HL-60 cell lines and normal lymphocytes were
used in a radioassay to measure TK1 activity. TK1 activity was measured by subtracting the
enzymatic activity with CTP as the phosphate donor from the total enzymatic activity with ATP
as the phosphate donor. The reasoning behind this is that TK2, an isozyme form of TK1 found in
mitochondria, favors CTP as the phosphate donor. By subtracting the enzymatic activity with
CTP as the phosphate donor, we ensure the remaining enzymatic activity is purely due to TK1
activity, as described by Lee and Cheng.44 Our data shows that the membrane fractions of Raji,
Jurkat, and HL-60 cell lines show TK1 enzymatic activity (Figure 2-9). Moreover, these
membrane fractions show higher TK1 activity levels than those in normal lymphocytes. This
could be due to minimal presence of TK1 on the surface of normal lymphocytes.

Figure 2- 9. TK1 activity in membrane fractions.
Membrane fractions were isolated from normal lymphocytes, Raji, Jurkat, and HL-60 cells and then used as samples
in the TK1 radioassay. Normal lymphocytes show minimal TK1 activity. However, Raji, Jurkat, and HL-60
membrane fractions show significantly higher TK1 activity than normal lymphocytes. P-value ≤0.001= ***, P-value
≤0.0001= ****.
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Discussion
Burkitt’s lymphoma and acute lymphoblastic leukemia are complex diseases that affect
millions of children worldwide. They are also two of the fastest proliferating tumors in
humans.32,33 Rapid cellular proliferation and resisting apoptosis are two of the hallmarks of
cancer that we can clearly see in hematological malignancies, especially in BL and
ALL.1,34,37,38,45 Early events in the deregulation of the cell cycle can lead to rapid proliferation
and possible cancer. Current treatments for BL and ALL include combination chemotherapy
drugs that cause debilitating side effects in children, therefore, there is an immediate need to
identify new targets to treat BL and ALL through immunotherapy. This study provides a
potential novel target against these malignancies.
Our study shows that upregulation of TK1 can also be found on the membrane of
hematological malignancies. This upregulation can be due to increased levels of TK1 in the cell
during cellular division, an event that happens very frequently in most cancer, especially in BL
and ALL.32,33 Here we show the novel finding that multiple hematological cancer cell lines and
ALL clinical samples express high levels of TK1 on their surface. Interestingly, this is not seen
in resting or proliferating normal lymphocytes. TK1’s expression appears to be similar to that of
CD229 in multiple myelomas, where CD229 is upregulated only in malignant cells and remains
low/absent in normal lymphocytes.46
Additionally, our data suggest membrane TK1 is found in monomeric and dimer form
and has enzymatic activity suggesting that TK1 has a function on the membrane. The actual
function of membrane TK1 and the mechanism/pathway by which TK1 reaches the membrane
remain unknown. However, our data suggests that the origins of membrane TK1 are endogenous
and do not come from serum TK1. We believe that during rapid proliferation events in
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malignancy, as TK1 protein levels increase, TK1 interacts with one or several membrane
proteins in the ER. For example, SELZ6 and COPS6 are membrane proteins known to interact
with TK1.47–49 Both of these proteins also upregulate during malignancy events and are found in
greater quantities on the cellular membrane. Perhaps their interaction results in TK1 being
transported to the membrane, remaining there, or perhaps being released into the bloodstream to
be later found in the serum.
The findings presented in this study are important for the field as they represent the
discovery of a novel antigen on the surface of some cancer cells, which if used in conjunction
with current immunotherapeutic treatments, such as CAR T cells, has the potential to improve
treatments for different hematological malignancies.
Conclusion
TK1 is localized on the surface of Raji (Burkitt’s lymphoma), HL60 (acute
promyelocytic leukemia), and Jurkat (acute T cell leukemia) cell lines and ALL clinical samples,
and not on the surface of normal resting or proliferating lymphocytes and may be used as a target
to treat hematological malignancies.
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CHAPTER 3: Membrane Expression of Thymidine Kinase 1 and Potential Clinical Relevance in
Lung, Breast, and Colorectal Malignancies

The following chapter is taken from an article published in Cancer Cell International. All content
and figures have been formatted for this dissertation but it is otherwise unchanged.
Abstract
Lung, breast, and colorectal malignancies are the leading cause of cancer-related deaths
in the world causing over 2.8 million cancer-related deaths yearly. Despite efforts to improve
prevention methods, early detection, and treatments, survival rates for advanced stage lung,
breast, and colon cancer remain low, indicating a critical need to identify cancer-specific
biomarkers for early detection and treatment. Thymidine kinase 1 (TK1) is a nucleotide salvage
pathway enzyme involved in cellular proliferation and considered an important tumor
proliferation biomarker in the serum. In this study, we further characterized TK1’s potential as a
tumor biomarker and immunotherapeutic target and clinical relevance. We assessed surface
localization by flow cytometry and confocal microscopy in lung (NCI-H460, A549), breast
(MDA-MB-231, MCF7), and colorectal (HT-29, SW620) cancer cell lines. To evaluate TK1’s
clinical relevance, we compared TK1 expression levels in normal and malignant tissue through
flow cytometry and immunohistochemistry. We also analyzed RNA-Seq data from The Cancer
Genome Atlas (TCGA) to assess differential expression of the TK1 gene in lung, breast, and
colorectal cancer patients. We found significant expression of TK1 on the surface of NCI-H460,
A549, MDA-MB-231, MCF7, and HT-29 cell lines and a strong association between TK1’s
localization with the membrane through confocal microscopy. We found negligible TK1 surface
expression in normal healthy tissue and significantly higher TK1 expression in malignant tissues.
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Patient data from TCGA revealed that the TK1 gene expression is upregulated in cancer patients
compared to normal healthy patients. Our results show that TK1 localizes on the surface of lung,
breast, and colorectal cell lines and is upregulated in malignant tissues and patients compared to
healthy tissues and patients. We conclude that TK1 is a potential clinical biomarker for the
treatment of lung, breast, and colorectal cancer.
Introduction
Lung, breast, and colorectal malignancies are the leading causes of cancer-related deaths
in the world. These three cancers account for over 4.86 million cases diagnosed and over 2.8
million cancer-related deaths worldwide every year 50. Thus, lung, breast, and colorectal cancers
are a major health concern as over 11.7 million people are currently diagnosed and living with
these diseases worldwide and represent a substantial economic burden in countries of all incomes
50,51

.
Despite efforts to improve methods of prevention, early detection, and treatments,

survival rates for advanced stage lung, breast, and colon cancer remain low at 4%, 26%, and
13%, respectively 52. Therefore, there is an urgent need to identify cancer-specific biomarkers for
early detection and treatment of the leading cause of cancer-related deaths such as lung, breast,
and colorectal cancers 53,54.
Thymidine kinase 1 (TK1) is a nucleotide salvage pathway enzyme involved in cellular
proliferation and considered an important tumor proliferation biomarker 4,19,28,55. In serum, TK1
has been shown to be elevated in early events of malignancy, and thus, TK1 can serve as an early
detection biomarker 4,56,57. Moreover, serum TK1 has been found to be elevated in several
hematological and solid tumors including breast, lung, colorectal cancer, among others, and high
serum TK1 levels usually correlate with cancer grade and stage, increased T-values, and
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increased tumor size 4,17–19,22,55. Serum TK1 can be also used as a prognostic tool to monitor
responses to chemotherapy or surgery 3,22.
To further characterize TK1’s potential as a tumor biomarker, we evaluate TK1 as a
potential immunotherapeutic target. In this study, we evaluate the expression levels of membrane
TK1 on lung, breast, and colorectal cell lines using flow cytometry. We also show evidence that
TK1 is localized on the surface of lung, breast, and colorectal cell lines. In addition, we evaluate
TK1 expression levels in normal and malignant tissue to determine TK1’s clinical relevance.
These results suggest TK1 as a potential immunotherapeutic target.
Materials and Methods
Cell lines and cell culture conditions
Lung cancer cell lines NCI-H460 (ATCC® HTB-1770 ™) and A549 (ATCC® CCL-185
™), breast cancer cell lines MCF7 (ATCC® HTB22™) and MDA-MB-231 (ATCC® HTB26™), and colon carcinoma cell lines SW620 (ATCC® CCL-227™) and HT-29 (ATCC®
HTB38™) were purchased from ATCC (Rockville, MD). NCI-H460 and HT-29 cell lines were
grown in RPMI 1640 medium (Corning Life Sciences, VWR International, Radnor, PA)
supplemented with 2mM L-glutamine and 10% fetal bovine serum. MDA-MB-231, MCF7, and
SW620 cell lines were grown in DMEM medium (Gibco, Thermo Fisher, Waltham, MA)
supplemented with 4mM L-glutamine and 10% fetal bovine serum. A549 cells were grown in
DMEM/F-12 medium (Gibco, Thermo Fisher, Waltham, MA) supplemented with 4mM Lglutamine and 10% fetal bovine serum. L-glutamine and fetal bovine serum were purchased
from Thermo Fisher (Waltham, MA). The media was renewed every 2-3 days. For subculturing,
cells were detached using Accutase (Stem Cell Technology, Vancouver, Canada) and seeded in
1:3 or 1:6 ratios. All cells were cultured at 37°C with 5% CO2. All cell lines were authenticated
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by short tandem repeat (STR) analysis at the University of Arizona Genetics Core Facility during
our study.
Antibodies
We used 3 custom mouse monoclonal antibodies developed in our lab against TK1 (CB1,
A72, and A74) and a commercially available rabbit monoclonal antibody against TK1 (ab91651)
(Abcam, Cambridge, United Kingdom). CB1 binds to the C-terminal domain of TK1,
specifically to the active domain. A72 and A74 are against an immunodominant region not on
the TK1 C-terminal domain. These antibodies have been previously tested to work in ELISA,
immunohistochemistry, and Western blots to confirm their specificity 28,40,41. The three custom
antibodies were conjugated to FITC using a conjugation kit (EasyLink, Abcam, ab102884) and
stored in the dark at 4°C. The commercially available antibody (ab91651) was conjugated to
FITC or APC using a conjugation kit (EasyLink, Abcam, ab102884) and stored in the dark at
4°C. We used FITC-conjugated CB1, A72, A74, and APC-conjugated ab91651 for flow
cytometry, FITC-conjugated A72 for confocal microscopy, and unconjugated ab91651 was used
for Western blotting and immunohistochemistry.
Flow cytometry
Cells were rinsed with Dulbecco's phosphate-buffered saline (DPBS) and treated with
Accutase (Stem Cell Technology, Vancouver, Canada) at 37°C for 5-10 mins to allow for
detachment and then rinsed with their respective complete medium. Cells were pelleted and
resuspended at 1x106 cells/mL in Cell Staining Buffer (BioLegend, San Diego, CA) and 200uL
of cells were placed in individual microcentrifuge tubes and stained with 1 ug of FITCconjugated CB1, A72, A74, or APC-conjugated ab91651 for 30 minutes on ice in the dark.
Negative controls used were unstained cells, cells stained with isotype mouse and rabbit
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antibodies, and NFkB to confirm the integrity of the cell membrane. Cells were then washed
with Cell Staining Buffer and resuspended in 500uL of FACS buffer. FACS buffer was made
with phosphate-buffered saline (PBS), 2% calf serum (Thermo Fisher, Waltham, MA), 1 mM
EDTA (Thermo Fisher, Waltham, MA, CAS 6381-92-6), and 0.1% sodium azide (Sigma
Aldrich, St. Louis, MO, CAS 26628-22-8). We collected 1x104 events per sample in a flow
cytometer (Attune, Life Technologies, Carlsbad, CA) and data was analyzed using the FlowJo
software (FlowJo, Ashland, OR).
Confocal microscopy
Cells were grown on glass coverslips for 48 hours. Coverslips containing cells were
washed in DPBS and then incubated with either isotype control, NFkB, or A72-FITC for 30
minutes at 4°C on a rocking platform. Coverslips were then washed 3 times with DPBS for 10
minutes on a rocking platform. We then dipped the coverslips in 1X CellMask™ Deep Red
Plasma membrane stain (Thermo Fisher Scientific, Waltham, MA) for 10 mins at 37°C. The cells
were rinsed in DPBS and imaged immediately using an Olympus FluoView FV1000 confocal
laser scanning microscope (Olympus, Tokyo, Japan). Images were obtained using the Laser
Sharp Computer Software (Bio Rad Laboratories, Hercules, CA) and later processed in
Photoshop (Adobe Systems, San Jose, CA).
Cell surface protein isolation and Western blotting
To isolate the cell surface proteins, we used the Pierce™ Cell Surface Protein Isolation
Kit (Thermo Fisher Scientific, Waltham, MA, Cat # 89881). Briefly, the HT-29 cell line was
grown to 90% confluency in T75 flasks and their media was removed. The cells were washed
with ice-cold PBS (provided in the kit) and then the PBS was removed within 5 seconds. To
label the cells with biotin, cells were incubated with a biotin solution made by dissolving the
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contents of one vial of Sulfo-NHS-SS_Biotin (provided in the kit) in 48mL of ice-cold PBS.
10mL of the biotin solution were added to each flask of cells and the flasks were incubated on a
rocking platform with gentle agitation for 30 mins at 4°C. After incubation, 500uL of quenching
solution (provided in the kit) were added to each flask to quench the reaction. Then, cells were
gently scraped and transferred to a conical tube and pelleted at 500 x g for 3 minutes, after which
the supernatant was discarded. Cells were then washed with 5mL of Tris-buffered saline (TBS,
provided in the kit) by pipetting up and down twice with a serological pipette and pelleted at 500
x g for 3 minutes. A cocktail of protease inhibitors (HaltTM Protease & Phosphatase Inhibitor
Cocktail, Thermo Fisher, Waltham, MA, product # 78440) was added to 500uL of lysis buffer
(provided in the kit) and added to the cell pellet. The cells in lysis buffer were transferred to a
microcentrifuge tube and resuspended in the fluid by pipetting up and down. The cells were then
disrupted using a cell disruptor (Sonicator 3000, Misonix, Inc., Farmingdale, NY) at low power
(1.5) on ice using five 1-second bursts. Cells were incubated for 30 minutes on ice, vortexed
every 5 minutes for 5 seconds, and sonicated for 1 second at low power (1.5) every 10 minutes.
The cell lysate was centrifuged at 10,000 x g for 2 minutes at 4°C and the clarified supernatant
transferred to a new microcentrifuge tube. To isolate the biotin-labeled proteins, the clarified
supernatant was added to a column that contained 500uL of NeutrAvidin Agarose that had been
previously washed with 500uL of wash buffer and centrifuged for 1 minute at 1000 x g. The
column was capped and incubated for 60 minutes at room temperature with end-over-end mixing
using a rotator. Then, the column was centrifuged for 1 minute at 1000 x g and the flow-through
was discarded. The column was washed 3 times with 500uL of wash buffer containing a cocktail
of protein inhibitors to remove any other cytoplasmic proteins. To elute the membrane proteins, a
50mM DTT solution was made by adding 23.7uL of 1M DTT (provided in the kit) to 450uL
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SDS-PAGE sample buffer. 450uL of DTT solution were added to the column and incubated for
60 minutes at room temperature with an end-over-end mixing on a rotator. The column was then
centrifuged for 2 minutes at 100 x g and the flow-through collected and stored at -20°C. For
Western blot analysis, samples were thawed on ice after which they were boiled for 5 minutes
and then run on a 12% acrylamide SDS gel at 90 V for 2-3 hours. The proteins on the gel were
transferred onto a nitrocellulose membrane at 90 V for 50 minutes in a cold room. The
nitrocellulose membrane was blocked with 5% non-fat milk in DPBS for 1 hour at 4°C in a
rotating platform and then incubated in anti-TK1 commercial antibody (ab91651) in a 1:1000
dilution in milk overnight at 4°C in a rotating platform. The nitrocellulose membrane was
washed 3 times in DPBS for 3 minutes each in a rotating platform and then incubated with a
IRDye 800 donkey anti-rabbit secondary antibody for 1 hour at 4°C in a rotating platform (LICOR, Lincoln, NE). Finally, the membrane was washed 3 times with DPBS and imaged in an
Odyssey CLx Imaging System (LI-COR, Lincoln, NE).
Tissue dissociation and analysis
Healthy and malignant colon tissues were obtained from Utah Valley Regional Medical
Center in Provo, UT under informed consent and following a protocol established by Utah
Valley Regional Medical Center. Tissues were minced into 3-4 mm pieces with a sterile scalpel.
Minced tissue was washed with 1X Hank’s Balanced Salt Solution (HBSS) (Thermo Fisher,
Waltham, MA) containing 5% FBS. Collagenase type II or type IV (both from Thermo Fisher,
Waltham, MA, product # 17101015 and # 17104019, respectively) was added to the minced
tissue and incubated at 37°C for 4-8 hours to allow for cell dissociation. To obtain a cell
suspension and separate dispersed cells from larger tissue pieces, cells were filtered through a
100um nylon mesh cell strainer (BD Biosciences, San Jose, CA). To prepare cells for flow
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cytometry analysis, cells were washed twice with HBSS and then resuspended in Cell Staining
Buffer. Cells were treated with Fc block (Human TruStain FcX™, BioLegend, San Diego, CA),
anti-human CD45 antibody (clone 2D1, eBioscience, San Diego, CA) and PI to gate out resident
lymphocytes and dead cells. We collected 2x104 events per sample in a flow cytometer (Attune,
Life Technologies, Carlsbad, CA) and data was analyzed using the FlowJo software (FlowJo,
Ashland, OR).
TK1 gene expression bioinformatics analysis
First, we evaluated differences in expression levels of the TK1 gene in 2,645 tumor
samples and 264 normal samples from The Cancer Genome Atlas.58 We used RNA-Sequencing
data that had been summarized at the gene level to transcripts-per-million units and processed
using the featureCounts algorithm.59,60 We also log-transformed the data values. These data
included expression values from tumor-adjacent and blood samples; these samples were often,
but not necessarily, matched to the tumor samples. Second, we evaluated breast-cancer samples
from The Cancer Genome Atlas for which hormone-receptor status had been determined via
immunohistochemistry; we limited this analysis to tumors that either were 1) positive for HER2
expression or 2) negative for HER2, ER, and PR expression. In calculating differences in
expression between these groups, we used a two-sided, Mann-Whitney U Test. We also
evaluated the level of correlation between TK1 and six stemness and EMT genes (CD44, SNAI1,
SNAI2, TWIST1, ZEB1, TGFB1) using Spearman’s method. We wrote scripts in the Python
programming language (https://python.org, v.3.6.1) to parse and prepare the data. We used the R
(v.3.2.2) statistical software and the ggplot2 software package (v.2.2.1) to generate graphs
illustrating these expression levels.61,62
Immunohistochemistry
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Lung, breast, and colorectal tissue microarrays were purchased from US Biomax
(Rockville, MD, catalog # LC2084, #BR721, and #CO1002b). Each slide contains at least 40
tissue cores with tissues varying in grade and stage and, and normal healthy tissues. The slides
were incubated in Histo-Clear (National Diagnostic, Atlanta, GA) for 10 mins for 3 changes to
remove paraffin. The slides were then incubated in 100% EtOH for 2 changes for 3 min each,
then in 90% EtOH for 2 changes for 1 min each, then in 70% EtOH for 1 change for 1 min. The
slides were then washed in ddH2O for 5 mins. To perform antigen retrieval, the slides were
incubated in DIVA Decloaker (Biocare Medical, Pacheco, CA) at 80- 95 °F for 30 mins and let
them cool for 10 mins. We then washed 2X in ddH20 for 5 mins. To perform peroxidase
quenching, the slides were washed in Tris-buffered saline (TBS) containing 3% hydrogen
peroxide for 20 mins and then washed 2X with TBS-T for 3 mins. The slides were blocked for
15 mins using a Background Sniper Block (Biocare Medical) to reduce background and then
washed with TBS twice for 3 mins. We incubated the slides with a 1:200 dilution of anti-TK1
(Abcam, ab91651) anti-GAPDH (positive control, mouse monoclonal, Cell Signaling
Technologies), and universal negative control serum (negative control, Biocare Medical) and put
them in a humidity chamber to prevent drying. After primary antibody staining, the slides were
washed 3X for 5 mins with TBS and incubated with MACH 4 Universal Horseradish Peroxidase
(HRP) Polymer (universal for rabbit/mouse secondary, Biocare Medical) for 30 mins in a
humidity chamber and then washed again 2X for 3 mins with TBS. We developed the slides with
ImmPACT DAB Peroxidase (HRP) substrate (Vector Laboratories, Burlingame, CA) and then
washed them 2X for 3 mins with TBS. We then stained the slides with Hematoxylin (Biocare
Medical) and rinsed them for 5 mins in running water. We mounted the slides using cover slips
and Cytoseal (Thermo Scientific) and imaged them using a light microscope. Images were
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analyzed using ImageJ open source software, using the “IHC (more brown)” plug-in to obtain
quantification using a gray scale 63. The lower the gray value, the darker the tissue is stained.
Statistical analysis
For our flow cytometry data, we used a multiple-comparisons one-way ANOVA test
using the Sidak’s correction for multiple comparisons to compare the expression of TK1 on the
surface of lung, breast, and colon cell lines vs isotype control. All samples were compared
against isotype mouse IgG except for Commercial, which was compared against isotype rabbit
IgG. We set a significant P-value at ≤0.05. Error bars represent the standard error of the mean.
For our IHC analysis, we used Tukey’s multiple comparison test to compare the means of each
group to one another. One side P-value was set to ≤0.05. Error bars represent the standard
deviation of the samples. We used Prism 7 (GraphPad, La Jolla, CA) to perform our statistical
analysis and produce graphs for most analysis. We the R (v.3.2.2) statistical software and the
ggplot2 software package (v.2.2.1) to generate graphs for TK1 gene expression bioinformatics
analysis.
Results
TK1 expression is elevated on the surface of NCI-H460, A549, MCF7, MDA-MB-231, SW620,
and HT-29 cells
Using flow cytometry, we observed an overall increase in fluorescence intensity in NCIH460, A549, MCF7, MDA-MB-231, SW620, and HT-29 cells (Supplemental Figure 1). The
data represents 8 independent staining procedures. Cells stained with A72 showed a significant
increase in fluorescence in all cell lines but SW620 and A529 (*P≤0.05; **P≤0.005;
***P≤0.001). Cells stained with CB1 showed significant increase in fluorescence in all cells but
MDA-MB-231 and A549 (Figure 3-1 A-D) (*P≤0.05; **P≤0.005; ***P≤0.001; ns=P>0.05).
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Cells stained with ab91651 all showed to have an increase in fluorescence except SW620 cells
(*P≤0.05; **P≤0.005; ***P≤0.001; ns=P>0.05). Overall, cells bound to CB1 had the lowest
increase in fluorescent intensity. We used an anti-NFkB antibody as a non-specific control as
well as an intracellular control. It allowed us to test whether the cells were intact, and the
fluorescent intensity change was due to punctured/dead cells or intact cells.
Data revealed that the lung cell lines NCI-H460 and A549 had the highest TK1 surface
expression out of all the other cell lines, followed by breast cell lines MDA-MB-231 and MCF7,
and colorectal cell line HT-29 (Figure 3-1 B, 3-1 C). The SW620 cell line showed very little
expression of TK1 on its surface, only and average of 10% of fluorescence total increase in cells
bound to A72, A74, and CB1, and only 2.7% in cells bound to commercial antibody ab91651
(Figure 3-1 A). These results suggest that 5 of the 6 cell lines tested expressed TK1 on their cell
surface.
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Figure 3- 1. Flow cytometry analysis of TK1 expression on the cell membrane of colon, breast, and lung cancer cell
lines.
A) Flow cytometry histograms of cell lines treated with anti-TK1 antibodies. Cells treated with anti-TK1 antibodies
(black line) showed a shift in fluorescence compared to isotype controls (gray area). B) Quantification of TK1
expression on the cell membrane of HT-29 and SW620 cell lines stained with FITC or APC-conjugated anti-TK1
antibodies. C) Quantification of TK1 expression on the cell membrane of MCF7 and MDA-MB-231 cell lines. The
top bar graph shows MCF7 and MDA-MB-231 cell lines stained with FITC or APC-conjugated anti-TK1
antibodies. D) Quantification of TK1 expression on the cell membrane of NCI-H460 and A549 cell lines stained
with FITC or APC-conjugated anti-TK1 antibodies. Statistical analysis was performed by comparing the mouse
isotype control fluorescent levels to those of A72, A74, CB1, or ab91651. *P≤0.05; **P≤0.005; ***P≤0.001;
ns=P>0.05
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TK1 is strongly associated with the membrane of NCI-H460, MDA-MB-231, and HT-29 cells
To visualize TK1’s localization and to ensure antibody binding was to the membrane
only, we performed confocal microscopy in HT-29, MDA-MB-231, and NCI-H460 cells since
these cell lines expressed high levels of TK1 on their membrane in flow cytometry. We stained
the cells with isotype control, anti-NFkB, and anti-TK1 (A74) antibodies conjugated to FITC.
We used intact cells to ensure FITC signals were not coming from intracellular TK1. We
obtained single channel images, rhodamine for membrane, FITC for isotype IgG, A74 and
NFKB antibodies, and overlaid them to observe associations between the signals. We observe
minimal FITC signals for cells stained with isotype IgG and NFkB. However, we observe a
much stronger signal from cells treated with anti-TK1 antibody (A74) (Figure 3-2). These
images show a clear colocalization of TK1 antibody signal and membrane dye, confirming the
presence of TK1 on the surface of HT-29, MDA-MB-231, and NCI-H460 cells.
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Figure 3- 2. TK1 co-localizes with the plasma membrane of lung, breast, and colon cancer cell lines.
NCI-H460, HT-29, and MD-MBA-231 cells were stained with FITC-conjugated antibodies and a cell membrane
specific dye (Rhodamine). Unstained cells, cells stained with isotype antibody, and cells stained with anti-NFkB
antibody (FITC) were used as controls to determine the viability of cells and the non-internalization of the
antibodies to prevent false positives. FITC images show staining on cells treated with anti-TK1 antibody A74. The
FITC images were merged with the Rhodamine images, which show the plasma membrane. The images show a
clear co-localization of TK1 with the plasma membrane of these cells
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Additionally, plasma membrane proteins were isolated from the HT-29 cell line. The
membrane proteins and cell extract were run on a 12% acrylamide SDS gel and then transferred
to a nitro cellulose membrane and probed with anti-TK1 antibody (ab91651). We observe that
TK1 is found in the membrane protein fraction of these cells further confirming the localization
of TK1 on the membrane (Figure 3). Moreover, the plasma membrane and cytosolic protein
fractions show oligomeric forms of TK1 (dimer and tetramer).

Figure 3- 3. Western blot of membrane proteins isolated from HT-29 cells probed with anti-TK1 antibody ab91651.
Membrane proteins from HT-29 were biotinylated and isolated for Western blot analysis. Controls included
membrane protein isolation from non-biotinylated cells and cell extracts. The results show TK1 is found in the
membrane of HT-29 cells in monomeric (~25 kDa) and dimeric forms (~50 kDa).
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Membrane TK1 expression is significantly lower in normal colon than malignant colon clinical
samples
To maintain a healthy gastrointestinal health, the lining of the gastrointestinal track needs
to undergo constant cell proliferation 64. Since TK1’s levels are proliferation-dependent, we
wanted to test whether healthy normal colon cells expressed TK1 on their membrane to ascertain
the clinical relevance of TK1 as biomarker target in colorectal cancer patients. We stained
dissociated healthy and malignant colon tissue with anti-human CD45 antibody and PI to gate
out resident lymphocytes and dead cells, and with anti-TK1 ab91651 and CD44 (positive control,
adhesion protein) antibodies to test for surface expression of these two proteins. Flow cytometry
revealed that the healthy normal colon tissue we tested (n=7) showed negligible expression of
TK1 on the membrane when compared to isotype control (rabbit) (P=0.8004). Malignant colon
tissue (n=7), however, showed significantly higher expression of TK1 on the membrane
compared to normal colon tissue (P=0.0002) (Figure 3-4). CD44 expression levels were not
significantly different between healthy normal and malignant colon tissues (P= 0.6634). These
results are crucial in establishing clinical relevance of TK1’s localization on the membrane as a
unique event in cancer and not a proliferation-dependent event.
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Figure 3- 4. Flow cytometry evaluation of TK1 expression on the surface of colorectal patient tissue.
Healthy normal and malignant colon tissue was dissociated into a single cell suspension solution and stained with anti-TK1
antibody 91651, isotype control, anti-CD44 (positive control), and anti-NFkB (negative control). Unstained cells were also used
as a negative control. A) Flow cytometry histograms showing normal and malignant colon tissue stained with isotype control
(gray area) and anti-TK1 antibody ab91651 (black line). There is a definitive shift in fluorescence in the malignant cells treated
with ab91651, whereas there is no shift in fluorescence in the normal colon cells treated with the same antibody. B)
Quantification and analysis of flow cytometry data on the expression of TK1 on the surface of normal and malignant colon.
Malignant colon tissues show a significantly higher expression of TK1 on their membrane compared to normal colon tissues
(P=0.002). Normal colon tissues show comparable results to those of the isotype control (P=0.8004), suggesting TK1 expression
on the surface of normal colon tissues is negligible.
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TK1 levels are significantly higher in malignant vs. normal healthy tissue
We stained lung, breast, and colon tissue arrays containing healthy normal, healthy
normal adjacent, cancer adjacent, and malignant tissue with anti-TK1 antibodies to establish
overall expression of TK1. We imaged all tissues with a light microscope at 20X. We conducted
the analysis using a gray scale. The lower the gray value, the darker the staining. There was a
significant increase in TK1 expression in malignant tissues compared to normal healthy tissues,
where TK1 expression was negligible (Figures 3-5, 6, 7). However, there was also a portion of
malignant tissues that stained negative for TK1 (Table 3-1).

TK1 staining in normal and malignant tissue
Tissue type

Negative

Positive

Lung adenocarcinoma

20

23

Lung squamous cell carcinoma

35

94

Normal lung

40

0

Cancer adjacent normal lung

10

0

Breast ductal carcinoma

6

19

Normal breast

24

0

Colon adenocarcinoma

9

26

Normal colon

10

0

Table 3- 1. TK1 staining in normal and malignant tissue.
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Lung tissue array shows ~50% of the tissues stain positive for TK1 in both
adenocarcinoma and squamous cell carcinoma (Figure 3-5 A, Table 3-1). We also observe that
normal cancer adjacent tissue is negative for TK1 (Figure 3-5 A). We can observe a clear
differential expression between malignant and normal healthy tissue in both lung
adenocarcinoma and squamous cell carcinoma (Figures 3-5 B and 3-5 C). In breast tissue arrays,
infiltrating ductal carcinoma positive for TK1 has a significantly lower average gray value than
normal breast tissue stained for TK1 (Figure 3-6 A). TK1 staining localizes to the gland
structures (Figure 3-6 A) in TK1+ tissue. Gland structures or stroma did not stain with TK1
antibody in TK1- tissue (Figure 3-6 B). These binary results are also observed in colorectal tissue
arrays (Figure 3-7). However, metastatic adenocarcinoma stained negative for TK1 (n=9) (Figure
3-7 A). The darkest TK1 staining in colorectal adenocarcinoma can be found in groups of
atypical glandular structures as seen in Figure 3-7 B. TK1- colorectal adenocarcinoma tissue
shows no staining in the glandular structures (Figure 3-7 C).
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Figure 3- 5. Immunohistochemistry analysis of lung cancer tissue.
Lung cancer tissue arrays were stained with anti-TK1 antibody ab91651, GAPDH, or isotype antibody. GAPDH was used as a positive control to account for housekeeping gene
expression. The isotype antibody was used to account for background noise and non-specific binding. Tissues were imaged in a light microscope at 20X. Analysis was conducted
using a gray scale. The lower the gray value, the darker the staining. A) Quantitative analysis of lung cancer IHC staining. The top graph shows that there is a statistically
significant expression of TK1 in ~53% of the lung adenocarcinoma tissues and in ~58% of the lung squamous cell carcinoma tissues. The bottom graph shows the TK1 expression
next to GAPDH and isotype controls. Background levels show no statistical difference between malignant and normal healthy tissues. Malignant and normal healthy tissue
showed non-statistical difference in GAPDH expression, whereas TK1 expression did show a statically significant difference between TK1+ and TK1- tissues. B) Images
showing lung adenocarcinoma tissue positive and weakly positive for TK1, which we classified as TK1- with gray value quantification. The yellow circle in adenocarcinoma
TK1+ image corresponds to lung papillary adenocarcinoma formed by abnormal proliferation of glanduliform structures of papillary disposition. The adenocarcinoma TK1image shows pulmonary adenocarcinoma tissue with acinar pattern conformed by cells of convoluted nuclei, irregular membrane, and prominent central macronucleoli. The
yellow arrows correspond to a diffuse weak positive nuclear staining for TK1. c Images showing lung squamous cell carcinoma tissue positive and weakly positive for TK1,
which we classified as TK1- with gray value quantification. In the squamous cell carcinoma TK1+ image, the green line shows strong diffuse positive nuclear staining for TK1.
The green arrow shows cytoplasmic background where there is evidence of infiltration in the underlying stroma shown by positive immunostaining against TK1. In the squamous
cell carcinoma TK1- image, the red circle and arrows show weakly positive nuclear focal staining in poorly differentiated lung squamous carcinoma with solid pattern.
***P≤0.001; ns=P>0.05

Figure 3- 6. Immunohistochemistry analysis of TK1 expression in breast cancer tissue.
Breast cancer tissue arrays were stained with anti-TK1 antibody ab91651, GAPDH, or isotype antibody. GAPDH was
used as a positive control to account for housekeeping gene expression. The isotype antibody was used to account for
background noise and non-specific binding. Tissues were imaged in a light microscope at 20X. Analysis was conducted
using a gray scale. The lower the gray value, the darker the staining. A) Quantitative analysis of breast cancer IHC
staining. The top graph shows that there is a statistically significant expression of TK1 in 20% of the ductal carcinoma
tissues. The bottom graph shows the TK1 expression next to GAPDH and isotype controls. Background levels show
no statistical difference between malignant and normal healthy tissues. Malignant and normal healthy tissue showed
non-statistical difference in GAPDH expression, whereas TK1 expression did show a statically significant difference
between TK1+ and TK1- tissues. B) Image showing breast ductal carcinoma positive for TK1. The yellow circle
encloses a malignant gland structure corresponding to a moderately differentiated ductal carcinoma, and the arrow
shows strong nuclear staining against TK1 in approximately 25% of the cells. C) Image showing breast ductal
carcinoma negative for TK1. The green circle shows an atypical gland structure corresponding to moderately
differentiated ductal carcinoma negative for staining against TK1. The green arrow shows the tumor stroma conformed
by fibrotic tissue also negative for TK1. Overall, the tissues shown in figures 5b and 5c show what we observed in the
tissue’s average gray values represented in figure 5a, that some ductal carcinoma showed strong TK1 staining and some
showed negative TK1 staining. ***P≤0.001; ns=P>0.05
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Figure 3- 7. Immunohistochemistry analysis of TK1 expression in colon cancer tissue.
Colon cancer tissue arrays were stained with anti-TK1 antibody ab91651, GAPDH, or isotype antibody. GAPDH was
used as a positive control to account for housekeeping gene expression. The isotype antibody was used to account for
background noise and non-specific binding. Tissues were imaged in a light microscope at 20X. Analysis was conducted
using a gray scale. The lower the gray value, the darker the staining. A) Quantitative analysis of colorectal cancer IHC
staining. The top graph shows that there is a statistically significant expression of TK1 in ~74% of the colon
adenocarcinoma tissues. The bottom graph shows the TK1 expression next to GAPDH and isotype controls. Background
levels show no statistical difference between malignant and normal healthy tissues. Malignant and normal healthy tissue
showed non-statistical difference in GAPDH expression, whereas TK1 expression did show a statically significant
difference between TK1+ and TK1- tissues. B) Image showing colorectal adenocarcinoma positive for TK1. The yellow
circle encloses an atypical glandular structure positive for TK1 in over 90% of the cells. c Image showing colorectal
adenocarcinoma negative for TK1. The circle an atypical glandular structure negative for TK1. Overall, the tissues shown
in figures 3-7B and 3-7C show what we observed in the tissue’s average gray values represented in figure 3-7A, that
some colorectal adenocarcinoma tissues showed strong TK1 staining and some showed negative TK1 staining.
***P≤0.001; ns=P>0.05
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TK1 gene expression levels are upregulated in malignant lung adenocarcinoma, lung squamous
carcinoma, breast invasive carcinoma, and colorectal adenocarcinoma
We also evaluated TK1 expression using RNA-Sequencing data from The Cancer
Genome Atlas. Our analysis reveals that TK1 levels are upregulated in both lung
adenocarcinoma and lung squamous cell carcinoma, breast invasive carcinoma, and colorectal
adenocarcinoma patients (Figure 3-8). Lung adenocarcinoma and lung squamous carcinoma
seem to be the malignancies with the most differential expression of TK1 between normal and
malignant patients, followed by breast invasive carcinoma, where we could also observe clear
differential expression (Figures 3-8 A, 3-8 B, and 3-8 C). There was some overlap in TK1
expression in colorectal adenocarcinoma patients vs. normal patients, probably due to the highly
proliferative nature of the colon, as TK1 levels rise during proliferation. However, TK1 levels in
colorectal adenocarcinoma patients are still more upregulated than in healthy normal patients
(Figure 3-8 D).
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TK1 gene expression in breast invasive carcinoma vs. normal breast patients. D) TK1 gene expression in colon adenocarcinoma vs. normal colon patients

A) TK1 gene expression in lung adenocarcinoma vs. normal lung patients. B) TK1 gene expression in lung squamous cell carcinoma vs. normal lung patients. C)

patients when compared to normal patients.

Figure 3- 8. Histograms of RNA-Sequencing data from The Cancer Genome Atlas showing increased TK1 gene expression in lung, breast, and colorectal cancer

Triple negative breast cancer patients show higher levels of TK1 than HER2+ cancer patients
We evaluated TK1 gene expression using RNA-Sequencing data from TCGA in breast
cancer patient available data for which hormone receptor status was available. Data was analyzed
by tumors that were either HER2+ status or HER2- and ER-, and PR- status (triple negative
breast cancer, TNBC). We found that TNBC tumor samples expressed higher levels of TK1 than
HER2+ tumor samples (Figure 3-9). These data seem consistent with membrane expression of
TK1 in MDA-MB-231 cells (TNBC), which express higher levels of TK1 on their surface than
MCF7 cells (HER2+) when stained with ab91651 antibody (Figure 3-1C).

Figure 3-9. Boxplot of RNA-Sequencing data from The Cancer Genome Atlas showing TK1 gene expression in
HER2+ breast tumors and triple negative breast cancer (TNBC) tumors.
The boxplot shows there is a significant upregulation in TK1 expression in TNBC tumors compared to HER2+ tumors.
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TK1 expression levels in triple negative breast cancer show positive correlation with stem cell
and EMT markers
RNA expression analysis was performed to evaluate the level of correlation between TK1
and six stemness and EMT genes (CD44, SNAI1, SNAI2, TWIST1, ZEB1, TGFB1). We found
that in TNBC TK1 expression levels positively correlated with CD44 (rho=0.24) and SNAI1
(0.13), and negatively correlated with SNAI2 (rho=-0.14), TGFB1 (rho=-0.13), TWIST1 (rho=0.02), and ZEB1 (rho=-0.35). On the other hand, we found that in HER2+ tumors, TK1
expression levels negatively correlated with all the markers (Figures 10 A-F). These results are
interesting, as it reveals that TK1 levels may correlate with stemness and invasion potential in
cancer cells.
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Figure 3-10. Scatterplots of RNA-Sequencing data from The Cancer Genome Atlas comparing TK1 expression to 6
stemness and EMT markers in HER2+ breast tumors and triple negative (TNBC) tumors.
A. Cell stemness marker CD44 is positively correlated to TK1 in TNBC tumors and negatively correlated to TK1 in
HER2+ breast tumors. B. EMT marker SNAI1 is positively correlated to TK1 in TNBC tumors and negatively
correlated to TK1 in HER2+ breast tumors. C. EMT marker SNAI2 is negatively correlated to TK1 in TNBC tumors
and in HER2+ breast tumors. D. EMT marker TWIST1 is negatively correlated to TK1 in TNBC tumors and in
HER2+ breast tumors. E. EMT marker ZEB1 is negatively correlated to TK1 in TNBC tumors and in HER2+ breast
tumors. F. Stemness and EMT marker TGFB1 negatively correlated to TK1 in TNBC tumors and in HER2+ breast
tumors.
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Discussion
The salvage pathway enzyme TK1 plays a crucial role in pyrimidine deoxynucleotide
synthesis during the cell cycle. Because of this critical association to proliferation and the cell
cycle, TK1 has been established as a proliferation biomarker in many cancers, including lung,
breast, and colorectal. Serum TK1 (sTK1) has been used in many applications for the early
detection and diagnosis of cancer, as it is found upregulated in cancer patients. In this study, we
present data supporting the expression and localization of TK1 on the cellular membrane of lung,
breast, and colon cancer, suggesting TK1 as a surface marker for these malignancies and a
different function for TK1 never reported before. The expression of TK1 on the surface of these
solid malignancies seems to mirror that of other surface/stem cell markers such as NCAM in
lung cancer, CD133 in lung and colon cancer, and CD298 in breast cancer 65–68. Our results also
correlated with some of our previous findings, which show that TK1 localizes on the surface of
hematological malignancies such as Burkitt’s lymphoma, acute lymphoblastic leukemia,
promyelocytic leukemia, and T-cell lymphoma cells 69. Interestingly, membrane TK1 seems to
be found in monomeric and dimer form similar to membrane TK1 found in hematological
malignancies, which suggest kinase enzymatic activity 69. The actual function of membraneexpressed TK1 is still unknown, however.
Moreover, we show that in colon patient tissue, a highly proliferative tissue, TK1 is
expressed on the membrane of only malignant cells and not healthy normal cells. This may mean
that TK1’s localization to the cell membrane is an event unique to malignancy. We have seen
similar results in the expression of TK1 in hematological malignancies vs. normal proliferating
lymphocytes, where TK1 only localized to the membrane of the cancer cells 69.
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We also report clinical data from The Cancer Genome Atlas, where we explore TK1 gene
expression levels, showing that TK1 levels are upregulated in lung, breast, and colorectal cancer
patients compared to their healthy normal patients. The bioinformatics analysis reveals that the
TK1 expression in some normal healthy tissues overlap with that of some malignant tissues. This
is an important observation for clinical relevance, as the gene expression results correlate with
our IHC results also shown in this study. IHC reveals that normal healthy tissue is negative for
TK1, but some malignant tissue stains positive for TK1 and some malignant stains weakly
positive or negative for TK1 in all lung, breast, and color tissue arrays. These results suggest that
not all malignancies will have TK1 as a biomarker.
Clinically speaking, a good surface biomarker will be one that overexpresses on the
membrane, shows stable expression levels in tumors, and is low or absent in normal cells/tissues
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. For example, the Erb-B2 Receptor Tyrosine Kinase 2 (HER2) is overexpressed in subsets of

breast, ovarian, gastric, colorectal, pancreatic and endometrial cancers 71. In breast and colon
cancer, HER2+ tumors are treated by targeting HER2 on the membrane72,73. Current treatments
include Herceptin (trastuzumab), Perjeta (pertuzumab), Tykerb (lapatinib), and Kadcyla (T-DM1
or ado-trastuzumab emtansine). Comparing HER2 and TK1, both proteins are heterogeneously
expressed in cancer tissues 20,74. Moreover, surface expression levels of HER2+ cancer cell lines
are comparable to surface expression of TK1. In fact, A549 and NCI-H460 cells lines show
higher expression of TK1 on the surface to breast and colon cancer cell lines reported in the
literature 75–77. We also report that TK1 gene expression levels are significantly higher in TNBC
vs. HER2+ breast tumors, suggesting TK1 as an alternative biomarker and potential target for
TNBC. We also show that in TNBC tumors, TK1 levels positively correlate with 2 stemness and
EMT markers, whereas in HER2+ tumors, TK1levels show the opposite correlation. This suggest
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that increased levels of TK1 may aid or have a function in invasion and migration potential in
cancer cells.
Further research is needed to help elucidate a mechanism by which TK1 reaches the cell
membrane and to understand the function of TK1 on the membrane. This will help answer why
some malignant tissues express TK1 and others do not. However, if the malignant tissue is
indeed positive for TK1, TK1 could potentially be used as an immunotherapeutic target, either
using antibodies against TK1, a drug-antibody conjugate, or a chimeric antigen receptor (CAR)
T cell targeting TK1.
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CHAPTER 4: TK1 Membrane Expression May Play a Role in the Invasion Potential of A549
Lung Cancer Cells

The following chapter is a manuscript submitted to the Journal of Cancer Therapy as a short
report. All content and figures have been formatted for this dissertation but it is otherwise
unchanged.

Abstract
Thymidine kinase 1 (TK1) is a well-studied cancer biomarker. It is commonly found
upregulated in the serum of cancer patients, and its levels correlate with stage and grade, disease
progression, and prognosis. It has recently been reported that TK1 localizes on the plasma cell
membrane of hematological and solid malignancies, and not on the membrane of normal healthy
cells, and while on the membrane, TK1 has enzymatic activity. However, the function of TK1 on
the surface membrane is not well understood. Here, we hypothesize that it may have a role in
tumor invasion and migration. It has been shown that TK1 expression levels positively correlate
with epithelia to mesenchymal transition (EMT) markers in patients with breast cancer as they
progress from HER2+ to triple negative breast cancer. In this study, we silenced TK1 expression
by siRNA and show that TK1’s membrane expression is significantly downregulated at 60 hours
post transfection. Using a Matrigel-based quantitative invasion assay, we measured cell invasion
potential in cells either expressing or lacking TK1 on their membrane and found that cells that
lack TK1 on their membrane exhibit decreased invasion potential. These results suggest that
TK1’s presence on the membrane may play a role in invasion and cell migration in cancer.
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Introduction
Thymidine kinase 1 (TK1) is a nucleotide salvage pathway enzyme primarily responsible
for converting deoxythymidine to deoxythymidine monophosphate, and upon subsequent
phosphorylation is incorporated into DNA 7. During normal cell proliferation, TK1 is usually
found in the cytoplasm where its expression is cell cycle-dependent, peaking during G1/S phase
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. TK1 levels can also increase in response to DNA damage, especially after chemotherapy and

radiotherapy. This increase is thought to provide cancer cells with a supply of nucleotides for
DNA repair rather than for proliferation, and serves as a support mechanism to promote the
survival of cancer cells 3. Due to its tight regulation by the cell cycle, TK1 has been extensively
studied in the context of cancer diagnostic biomarkers, where it has been shown to be
upregulated in tissue and serum in both solid tumors and hematological malignances. TK1’s
prognostic and diagnostic potential has been demonstrated using the traditional TK activity
radioassay for hematological malignancies and solid tumors including lung, breast, colon,
bladder, cervical, and colorectal 18,21,22,29–31. TK1 levels in serum have also been shown to have
diagnostic potential in bladder cancer, cervical carcinoma, gastric cancer, non-small cell lung
cancer, colorectal cancer, and renal cell carcinoma. In summary, high TK1 serum levels correlate
with tumor aggressiveness and can be indicative of early events in carcinogenesis 15,28. While
TK1 has mostly been studied as a cancer biomarker in the serum, we have recently shown that
TK1 localizes on the plasma membrane of cells and this is an event independent of proliferation
and appears to be exclusive to malignant cells. For these reasons, TK1 may be a novel target for
cancer immunotherapy. However, understanding TK1’s function on the membrane is important
as we approach the development of immunotherapy using TK1 as a target. Recently, it was
reported that TK1 expression levels correlate with EMT markers in breast cancer in clinical
samples as the disease progresses to triple negative breast cancer 79. Additionally, due to serum
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TK1 correlation with disease progression and aggressiveness, we hypothesized that membrane
TK1 could have an immunoregulatory role and could aid in the invasion potential of cancer cells.
In this study, we found that when membrane TK1 expression is silenced, cells lose invasion
potential. These results suggest that TK1 may have a role in migration and immunoregulation, as
well as in epithelial mesenchymal transitions (EMT).
Materials and methods
Cell line and cell culture
The non-small cell lung carcinoma A549 cell line was purchased from ATCC (Catalog #
CCL-185™) and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS) and 2mM L-glutamine (both from Thermo Fisher Scientific, Waltham, MA). Cells were
grown at 37 ºC and 5% CO2 and fed 2-3 times per week by removing the medium, rinsing the
cells with Dulbecco's Phosphate-Buffered Saline (DPBS, Gibco Thermo Fisher Scientific,
Waltham, MA), incubating them with Accutase (Stem Cell Technology, Vancouver, Canada) for
detachment and subculturing in a 1:4 ratio. For this experiment, cells were kept at a low passage
to ensure best transfection efficiency.
siRNA library
Three validated siRNA against TK1 and control siRNA (GAPDH) were purchased from
Thermo Fisher Scientific (catalog # 4390824, siRNA IDs s14158, s14159, and s14160 for TK1,
and catalog # 4390849 for GAPDH). siRNA was resuspended in nuclease-free water at 50uM,
aliquoted, and stored at -80 ºC. For working siRNA concentrations, siRNA was diluted to 10uM
in nuclease-free water.
Transfection
Two hundred-thousand A549 cells were plated in 6 well-plates overnight to allow for
attachment, after which, the medium was removed, and cells were washed with DPBS and 2mL
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serum-free RPMI 1640 was added to each well. Lipid-nucleic acid complexes of RNAiMAX
(Thermo Fisher Scientific, Waltham, MA, catalog # 13778030) and siRNA were prepared
according to the manufacturer’s instructions and added to the cells. 12 hours after transfection,
medium and lipid-nucleic acid complexes were removed from cells and fresh complete RPMI
1640 medium was added to the cells. Cells were used at 60 hours post transfection, as
recommended by manufacturer. (Cells treated with siRNA ID 14158 were named siRNA 58,
those treated with siRNA ID 14159 were named siRNA 59, and those treated with siRNA ID
14160 were named siRNA 60
Flow cytometry
Transfected A549 cells were rinsed with DPBS, treated with Accutase at 37°C for 5-10
mins to allow for detachment, and then rinsed with complete medium. Cells were pelleted and
resuspended at 1x106 cells/mL in Cell Staining Buffer (BioLegend, San Diego, CA) and 200uL
of cells were placed in individual microcentrifuge tubes and incubated with 5uL of Fc block
(Human TruStain FcX™, BioLegend, San Diego, CA) for 10 minutes at room temperature,
followed by incubation with 1 ug of anti-TK1 antibody (ab91651, Abcam, Cambridge, United
Kingdom) for 15 minutes on ice. Cells were then washed with 1 mLCell Staining Buffer,
incubated with anti-rabbit AlexaFluor647 antibody (Thermo Fisher, Waltham, MA, cat #
A27040) and incubated on ice in the dark for 15 minutes. Cells were washed 2X with Cell
Staining Buffer and resuspended in Fluorescence-activated cell sorting (FACS) buffer. FACS
buffer was made with phosphate-buffered saline (PBS), 2% calf serum (Thermo Fisher,
Waltham, MA), 1 mM EDTA (Thermo Fisher, Waltham, MA, CAS 6381-92-6), and 0.1%
sodium azide (Sigma Aldrich, St. Louis, MO, CAS 26628-22-8). We collected 1x104 events per
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sample in a flow cytometer (Accuri C6 Plus, BD Biosicences, San Jose, CA) and data was
analyzed using FlowJo software (FlowJo, Ashland, OR).
Invasion Assay
An xCELLigence RTCA DP instrument (Cat. 05469759001) was utilized to determine
real time invasion and cell motility of A549 cells either expressing TK1 on their surface or after
TK1 silencing. Invasion was assessed in 16 well CIM-Plates (Cat. 05665817001) (n=4)
composed of an upper and lower chamber, each containing 16 wells. The top wells were coated
with a 1:40 matrigel concentration and incubated for 4 hr. Cells were plated in the top chamber at
a concentration of 50,000 cells/well in serum-free RPMI in a total volume of 100µL in the
presence of the cells' corresponding media. The cells were allowed to migrate toward the bottom
chamber wells which were filled with 160 µL of 10% FBS growth medium, as a source of
chemoattractant (directional migration). The cells were then placed in the RTCA DP instrument
and invasion readings were taken every 5 minutes for 24hr.
Statistical analysis
The flow cytometry data was analyzed with a one-way ANOVA test using the Sidak’s
correction for multiple comparisons to compare the expression of TK1 on the surface of the
siRNA treated cells vs. isotype control. P-value significance was set at ≤0.05. Error bars
represent the standard error of the mean. Statistical analyses were performed using Prism
software.
Results
Flow cytometry
To asses TK1 silencing on the surface of A549 cells, a cell line known to express high
levels of membrane TK1, we stained the control and siRNA treated cells with antibodies against
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TK1. Flow cytometry revealed that A549 cells treated with siRNA targeting TK1 displayed
decreased expression of TK1 on the surface. Cells treated with siRNA 58 and siRNA 59 showed
significant reduction of TK1 on the surface, while siRNA 60 did not show a significant reduction
(Figure 4-1). Cells treated with siRNA 58 had the most dramatic silencing in TK1 surface
expression with a 93.82% reduction in surface expression compared to cells treated with control
siRNA. Cells treated with siRNA 59 showed a 15.98% reduction at 60 hours post transfection.

Figure 4- 1. Membrane expression of TK1 at 60 hours post siRNA transfection by flow cytometry.
A) Histrograms showing membrane expression of TK1 compared to GAPDH and HLA. A549 cells transfected with
siRNA 58 show a significant shift to the left when stained with TK1 antibody, suggesting decreased TK1 expression
on the surface. B) Quantification of flow cytometry data showing the percentage of cells positive for APC stain. C)
Quantification of flow cytometry data showing that transfection with siRNA 58 in A549 cells decreases TK1
expression by 93.82%.
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Invasion study
To compare the invasion potential of A549 cells, with and without TK1 surface
expression in vitro, we performed an invasion assay with A549 cells treated with control siRNA,
siRNA 58, siRNA 59, and siRNA 60. In our study, the invasion potential of cells was measured
by the cells crossing a layer of matrigel from serum-free medium towards complete medium, as
they seek nutrients. In our results, we observed that when TK1 is highly silenced on the
membrane, the invasion potential is reduced. In fact, only cells treated with siRNA 58, which
had the most reduction of membrane TK1 expression, showed a significant reduction in invasion
potential. Cells treated with siRNA 59 and siRNA 60 were statistically equally invasive to cells
treated with control siRNA (Figure 4-2). We observed no change in cell viability before the
invasion assay. Due to the short window of time post transfection, we did not evaluate growth
rates. However, cell counts were similar between all transfected samples, so we assume there is
no variability in cell growth rates.

Figure 4- 2. Invasion assay with A549 cells transfected with TK1 siRNA.
Only A549 cells that had a drastic TK1 silencing show decreased invasion compared to control siRNA.
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Discussion
TK1 has been studied as a serum biomarker since the late 80’s. While its clinical application has
been proven to be useful as a monitoring tool for disease progression and prognosis of most
cancers, our group has found it to be a potential target in the clinic. TK1 was recently reported to
be differentially expressed on the membrane of hematological and solid malignancies compared
to normal cells. The localization of TK1 on the membrane appears to be an event unique in
malignancy, as highly proliferative tissue like colon or normal lymphocytes induced to divide do
not express TK1 on their surface. This posed the question as to why malignant cells upregulate
TK1 on their surface and what the advantage in malignancy is. Recently, it was reported that
stemness and EMT makers were more positively and strongly correlated to TK1 levels in triple
negative breast cancer compared to HER2+ breast cancer, indicating that TK1 expression levels
may also correlate with tumor invasion potential (summarized in Table 4-1) 79. While not all
genes show positive correlations, there is a positive trend in the Spearman’ correlation
coefficients between TK1 expression and these cell stemness and EMT markers between HER2+
and TNBC patients. Here we report that when we silence TK1 on the surface of A549 cells, their
invasion potential decreases significantly. Further studies showing a connection of TK1 and
migration or EMT markers could elucidate a potential immunoregulatory function.
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Gene name

CD44

Function

HER2+: TK1 vs.

TNBC: TK vs.

gene (Spearman’s

gene (Spearman’s

correlation

correlation

coefficient)

coefficient)

0.14

0.24

-0.01

0.13

-0.3

-0.14

-0.34

-0.02

-0.36

-0.35

-0.23

-0.13

Cell–cell interactions,
cell adhesion and
migration. Stemness
marker.

SNAI1

Induction of epithelial to
mesenchymal transition.

SNAI2

Induction of epithelial to
mesenchymal transition.

TWIST1

Induction of epithelial to
mesenchymal transition.

ZEB1

Induction of epithelial to
mesenchymal transition.

TGFB

Induction of cell
migration and epithelial
to mesenchymal
transition.

Table 4- 1. Summary of Spearman’s correlation coefficients between TK1 and cell stemness or EMT markers in
HER2+ and TNBC patients.
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CHAPTER 5: Macrophage Polarization and its Role in Cancer

The following chapter is taken from an article published in the Journal of Clinical & Cellular
Immunology. All content and figures have been formatted for this dissertation but it is otherwise
unchanged.
Abstract
The immune system plays an important role in the development and progression of
cancer. Macrophages exhibit a variety of responses according to varying stimuli, and express
different functions depending upon the microenvironment surrounding them. Macrophages can
be pro-inflammatory (M1) or anti-inflammatory (M2). Research studies have shown that
infiltration of macrophages can account for >50% of the tumor mass in some cancers, aid in
metastasis by inducing angiogenesis, and signify a poor prognosis. Macrophages that migrate to
the tumor site, remain there, and aid in angiogenesis and metastasis are termed tumor associated
macrophages (TAMs) and are thought to express an M2 phenotype. This review will examine the
polarization states of macrophages, their functions and role in cancer, their activation pathways
and metabolism, and potential approaches to cancer immunotherapies using macrophages.
Introduction
Cancer is a group of diseases that involve unregulated cell growth and death, genome
instability and mutations, tumor-promoting inflammation, induction of angiogenesis, evasion of
the immune system, dysregulation of metabolic pathways, immortal cell replication, and
activation of metastasis and invasion.1 Cancer is the second leading cause of death in the United
States after heart disease, and more than 1.6 million new cases are expected to be diagnosed each
year. More than 580,000 Americans are expected to die yearly from cancer (about 1600 cancer
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deaths per day), nearly 1 in 4 of all deaths
overall.80,81<sup>82</sup><sup>81</sup><sup>72</sup>
The immune system plays an important role in the development and progression of
cancer. In fact, immune cell infiltration to the tumor site can affect malignancy progression and
metastasis.83,84 Infiltration of macrophages to the tumor site has been shown to account for more
than 50% of the tumor mass in certain breast cancer cases, suggesting macrophages have a
significant role in tumor progression.85–87
Macrophages are cells derived from the myeloid lineage and belong to the innate immune
system. They are derived from blood monocytes that migrate into tissue. One of their main
functions is to phagocytose microbes and clear cellular debris. They also play an important role
in both the initiation and resolution of inflammation.88,89 Moreover, macrophages can exhibit
different responses depending on the type of stimuli they receive from the surrounding
microenvironment, varying from pro-inflammatory to anti-inflammatory.90 In fact, two major
macrophage phenotypes have been proposed: M1 and M2, which correspond to the extreme
phenotypes of a spectrum of responses.
M1 macrophages are activated upon contact with certain molecules such as
lipopolysaccharide (LPS), IFN-γ, IL-1β, TNF-α, and Toll-like receptor engagement, whereas M2
macrophages, also known as alternatively activated macrophages, exhibit immunomodulatory
effects, tissue repair, and angiogenesis properties and can recruit regulatory T cells to
inflammation sites. M2 macrophages are activated by anti-inflammatory cytokines such as IL-4,
IL-13, and IL-10.91,92
The in vivo molecular mechanisms of macrophage polarization are poorly characterized
because of the variety of signals macrophages experience in the cellular microenvironment.88,93
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In recent years, progress has been made in identifying in vivo macrophage polarization under
physiological conditions, especially during ontogenesis and pregnancy, and during pathological
conditions such as allergies, chronic inflammation, and cancer. However, several macrophage
populations are observed during specific pre-clinical and clinical conditions, as a result of the
complex signaling between the tissue microenvironment and the immune system.90 We do know,
however, that in vitro macrophage polarization is plastic, and macrophages exposed to specific
cytokines, can be polarized back and forth to either phenotype.94,95 Interferon gamma (IFN-γ)
and IL-4 are two cytokines that can polarize macrophages to M1 and M2 phenotypes,
respectively.94
The presence of macrophages is crucial in tumor progression and growth, and has
implications in determining prognosis.96,97 Because macrophages can exhibit both proinflammatory and anti-inflammatory properties, it is important to understand their polarization
and function in tumor progression and metastasis.
This review discusses the characteristics and functions of polarized macrophages, their
role in cancer, their activation pathways and metabolic functions, and their use in potential
cancer immunotherapy approaches.
M1 Phenotype
M1 macrophages, or classically activated macrophages, are aggressive and highly
phagocytic, produce large amounts of reactive oxygen and nitrogen species, and promote a Th1
response.90 M1 macrophages secrete high levels of IL-12 and IL-23, two important inflammatory
cytokines. IL-12 induces the activation and clonal expansion of Th17 cells, which secrete high
amounts of IL-17, and thus contribute to inflammation.98 These characteristics allow M1
macrophages to control metastasis, suppress tumor growth, and control microbial infections.99
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Moreover, the infiltration and recruitment of M1 macrophages to tumor sites correlates with a
better prognosis and higher overall survival rates in patients with solid tumors.96,97,100–103
Inflammatory signals such as IFN-γ, TNF- α, IL-1ß and LPS can polarize macrophages to
the M1 phenotype in vitro.104,105 Transcription factors are also involved in the polarization of
macrophages. Classically activated macrophages initiate the induction of the STAT1
transcription factor which targets CXCL9, CXCL10 (also known as IP-10), IFN regulatory
factor-1 (IRF-1), and suppressor of cytokine signaling-1.106 In the tumor microenvironment,
Notch signaling plays an important role in the polarization of M1 macrophages, as it allows
transcription factor RBP-J to regulate classical activation. Macrophages that are deficient in
Notch signaling express an M2 phenotype regardless of other extrinsic inducers.107 MicroRNA
molecules (miRNAs) also regulate the polarization of macrophages. One crucial miRNA,
miRNA-155, is upregulated when macrophages are transitioning from M2 to M1, and M1
macrophages overexpressing miRNA-155 are generally more aggressive and are associated with
reduction of tumors.108 Moreover, miRNA-342-5p has been found to foster a greater
inflammatory response in macrophages by targeting Akt1 in mice. This miRNA molecule also
promotes the upregulation of Nos2 and IL-6, both of which act as pro-inflammatory signals for
macrophages.109 Other miRNAs such as miRNA-125 and miRNA-378 have also been shown to
be involved in the classical activation pathway of macrophages (M1).110
Classically activated macrophages are thought to play an important role in the recognition
and destruction of cancer cells, and their presence usually indicates good prognosis. After
recognition, malignant cells can be destroyed through several mechanisms, which include
contact-dependent phagocytosis and cytotoxicity (i.e. cytokine release such as TNF-α).99
Environmental signals such as the tumor microenvironment or tissue-resident cells, however, can
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polarize M1 macrophages to M2 macrophages. In vivo studies of murine macrophages have
shown that macrophages are plastic in their cytokine and surface marker expression and that repolarizing macrophages to an M1 phenotype in the presence of cancer can help the immune
system reject tumors.111
M2 Phenotype
M2 macrophages are anti-inflammatory and aid in the process of angiogenesis and tissue
repair. They express scavenger receptors and produce large quantities of IL-10 and other antiinflammatory cytokines.108,112 Expression of IL-10 by M2 macrophages promotes a Th2
response, and Th2 cells, in turn, upregulate the production of IL-3 and IL-4. IL-4 is an important
cytokine in the healing process because it contributes to the production of the extracellular
matrix.98 M2 macrophages exhibit functions that may help tumor progression by allowing new
blood vessel growth, which feeds the malignant mass of cells, thus promoting their growth. The
presence of macrophages (thought to be M2) in the majority of solid tumors negatively correlates
with treatment success and longer survival rates.83 Additionally, the presence of M2
macrophages has been linked to metastatic potential in breast cancer. Lin and colleagues (2006)
found that early recruitment of macrophages to the breast tumor sites in mice increases
angiogenesis and the incidence of malignancy.113
Single-marker identification of M2 macrophages reveals that they express CD163.
However, further studies used a double-staining immunohistochemistry approach to identify M2
macrophages in their own microenvironment using CD163/CD68 and pSTAT1, RBP-J, or
CMAF antibodies. These results showed that microenvironments from different model
conditions known to stimulate a Th1 or Th2 response are all different, revealing the complexity
of the microenvironment, thus making it hard to identify M2 macrophage populations in vivo.114
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It is thought that the tumor microenvironment helps macrophages maintain an M2
phenotype.98,115 Anti-inflammatory signals present in the tumor microenvironment such as
adiponectin and IL-10, can enhance an M2 response.116
Macrophage polarization
The tumor microenvironment significantly affects macrophage polarization. The process
of polarization can be diverse and complicated because of the complex environment of IL-10,
glucocorticoid hormones, apoptotic cells, and immune complexes that can interfere with the
function of innate immune cells.90,111 The mechanisms of polarization are still unclear, but we
know they involve transcriptional regulation. For example, macrophages exposed to LPS or IFNγ will polarize towards an M1 phenotype, whereas macrophages exposed to IL-4 or IL-13 will
polarize towards an M2 phenotype. LPS or IFN-γ can interact with Toll-like receptor 4 (TLR4)
on the surface of macrophages inducing the Trif and MyD88 pathways, inducing the activation
of transcription factors IRF3, AP-1, and NFκB and thus activating TNFs genes, interferon genes,
CXCL10, NOS2, IL-12, etc. which are necessary in a pro-inflammatory response.117 Similarly,
IL-4 and IL-13 bind to IL-4R and activate the Jak/Stat6 pathway, which regulates the expression
of CCL17, ARG1, IRF4, IL-10, SOCS3, etc., which are genes associated with an antiinflammatory response (M2 phenotype).
Other transcription factors associated with macrophage polarization either towards an M1
or M2 response are IRF5, IRF4, Krüppel-like factor 4 (KLF4), CCAAT/enhancer-binding
protein-β (C/EBPβ), PU.1, pSTAT1, RBP-J, and CMAF.93,114,118–120
Additional mechanisms of macrophage polarization include miRNA micromanagement.
miRNAs are small non-coding RNAs of 22 nucleotides in length that regulate gene expression
post-transcriptionally, as they affect the rate of mRNA degradation. Several miRNAs have been
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shown to be highly expressed in polarized macrophages, especially miRNA-155, miRNA-125,
miRNA-378 (M1 polarization), and miRNA let-7c, miRNA-9, miRNA-21, miRNA-146,
miRNA147, miRNA-187 (M2 polarization).110,120,121
Macrophage polarization is a complex process. In the past years, there has been much
controversy on the definition/description of macrophage activation and macrophage polarization.
A recent paper published by Murray et al. describes a set of standards to be considered for the
consensus definition/description of macrophage activation, polarization, activators, and markers.
This publication was much needed to clarify the definition and characterization of
activated/polarized macrophages 122.
Tumor Associated Macrophages (TAMs)
Cells exposed to a tumor microenvironment behave differently. For example, tumor
associated macrophages found in the periphery of solid tumors are thought to help promote
tumor growth and metastasis, and have a M2-like phenotype.123. Tumor associated macrophages
can be either tissue resident macrophages or recruited macrophages derived from the bone
marrow (macrophages that differentiate from monocytes to macrophages and migrate into
tissue). A study by Cortez-Retamozo (2012) found that high numbers of TAM precursors in the
spleen migrate to the tumor stroma, suggesting this organ as a TAM reservoir. TAM precursors
found in the spleen were found to initiate migration through their CCR2 chemokine receptor.124
Recent studies have found CSF-1 as the primary factor that attracts macrophages to the tumor
periphery, and that CSF-1 production by cancer cells predicts lower survival rates and indicates
an overall poor prognosis.125–127 Other cytokines such as TNF-α and IL-6 have also been linked
to the accumulation/recruitment of macrophages to the tumor periphery.125
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It is thought that macrophages that are recruited around the tumor borders are regulated
by an “angiogenic switch” that is activated in the tumor. The angiogenic switch is defined as the
process by which the tumor develops a high-density network of blood vessels that potentially
allow the tumor to become metastatic, and are necessary for malignant transition. In a breast
cancer mouse model, it was observed that the presence of macrophages was required for a full
angiogenic switch. When macrophage maturation, migration, and accumulation around the tumor
was delayed, the angiogenic switch was delayed as well, suggesting that the angiogenic switch
does not occur in the absence of macrophages, and that macrophage presence is necessary for
malignancy progression.128 Moreover, the tumor stromal cells produce chemokines such as
CSF1, CCL2, CCL3, CCL5, and placental growth factor that will recruit macrophages to the
tumor surroundings and provide an environment for macrophages to activate the angiogenic
switch, during which macrophages will produce high levels of IL-10, TGF-β, ARG-1 and low
levels of IL-12, TNF-α, and IL-6. The level of expression of these cytokines suggests
macrophages modulate immune evasion. It is important to point out that in solid tumors,
macrophages will be attracted by hypoxic environments and will respond by producing hypoxiainducible factor-1α (HIF-1α) and HIF-2α, which regulate the transcription of genes associated
with angiogenesis. During the angiogenic switch, macrophages can also secrete VEGF
(stimulated by the NF-κB pathway), which will promote blood vessel maturation and vascular
permeability.129
Tumor associated macrophages are thought to be able to maintain their M2-like
phenotype by receiving polarization signals from malignant cells such as IL-1R and MyD88,
which are mediated through the IκB kinase β and NF-κB signaling cascades. In fact, inhibition of
NF-κB in TAMs promotes classical activation.130 Moreover, another study suggested p50 NF-κB
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as the factor involved in suppression of M1 macrophages, and that the inflammation reduction
helped in tumor growth. When they created a p50 NF-κB knock-out mouse, they found out that
M1 aggressiveness was restored and that tumor survival was reduced.131
Because the tumor mass contains a great number of M2-like macrophages, TAMs can be
used as a target for cancer treatment. Reducing the number of TAMs or polarizing them towards
an M1 phenotype can help destroy cancer cells or impair tumor growth.132–134 Luo and
colleagues in a study published in 2006, used a vaccine against legumain, a cysteine protease and
stress protein upregulated in TAMs, as a potential tumor target. When the vaccine against
legumain was administered to mice, the results showed that the angiogenesis genes were downregulated and tumor growth was halted.133
Metabolism and activation pathways
Metabolic alterations present in tumor cells are controlled by the same mutations that
produce cancer.135,136 As a result of these metabolic alterations, cancer cells are able to produce
signals that can modify the polarization of macrophages and promote tumor growth.137,138
M1 and M2 macrophages demonstrate distinct metabolic patterns that reflect their dissimilar
behaviors.139 The M1 phenotype is characterized by increased glycolysis and glucose metabolism
which is skewed towards the oxidative pentose phosphate pathway, decreased oxygen
consumption, and the production of large amounts of radical oxygen and nitrogen species, as
well as inflammatory cytokines such as TNF-α, IL-12, and IL-6.139,140 The M2 phenotype is
marked by increased fatty acid intake and fatty acid oxidation, decreased flux towards the
pentose phosphate pathway, increased overall cell redox potential, and upregulated scavenger
receptors and immunomodulatory cytokines such as IL-10 and TGF-β.139
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Multiple metabolic pathways play important roles in macrophage polarization. Protein
kinases, such as Akt1 and Akt2, alter macrophage polarization by allowing cancer cells to
survive, proliferate, and use an intermediary metabolism 141. Other protein kinases can direct
macrophage polarization through glucose metabolism by increasing glycolysis and decreasing
oxygen consumption.140,142 Shu and colleagues were the first to visualize macrophage
metabolism and immune responses in vivo, using a PET scan and a glucose analog.143
L-arginine metabolism also exhibits discrete shifts important to cytokine expression in
macrophages and is exemplary of distinct metabolic pathways altering TAM-tumor cell
interactions.144 Classically activated (M1) macrophages favor inducible nitric oxide synthase
(iNOS). The iNOS pathway produces cytotoxic nitric oxide (NO), and cells consequently
exhibits anti-tumor behavior. Alternatively activated (M2) macrophages have been shown to
favor the arginase pathway, and produce ureum and l-ornithine, which contribute to progressive
tumor cell growth.144,145
Direct manipulation of metabolic pathways can alter macrophage polarization. The
carbohydrate kinase-like (CARKL) protein, which plays a role in glucose metabolism, has been
used to alter macrophage cytokine signatures.139,140 When CARKL is knocked down by RNAi,
macrophages tend to adopt an M1-like metabolic pathway (metabolism skewed towards
glycolysis and decreased oxygen consumption), whereas when CARKL is overexpressed,
macrophages adopt an M2-like metabolism (decreased glycolytic flux and more oxygen
consumption) 139. When macrophages adopt an M1-like metabolic state through LPS/TLR4
engagement, CARKL levels decrease and the macrophages activate genes controlled by the NFκB pathway such as TNF-α, IL-12, and IL-6, while also increasing cell redox potential by
increasing concentrations of NADH:NAD+ and GSH:GSSSG complexes. During an M2-like
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metabolic state, macrophages upregulate CARKL and genes regulated by STAT6/IL-4 (IL-10
and TGF-β).
Obesity can also affect macrophage polarization. Obesity is associated with a state of
chronic inflammation, an environment that drives the IL4/STAT6 pathway to activate NKT cells,
which further activate macrophages towards an M2 response. During late-stage diet-induced
obesity, macrophages migrate to adipose tissue, where immune cells alter levels of TH1 or TH2
cytokine expression in the adipose tissue, causing an M2 phenotype bias and possibly increased
insulin sensitivity.146
Switching the environment to a M1 phenotype bias by targeting metabolic pathways in
TAMS may offer an alternative means of reducing tumor growth and metastasis.
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Figure 5- 3. Macrophage polarization is a spectrum.

Macrophage immunotherapy approaches against cancer
Cancer immunotherapy involves stimulation of the immune system to recognize, reject,
and destroy cancer cells. Cancer immunotherapy with macrophages has the goal to polarize
macrophages towards a pro-inflammatory response (M1), thus allowing the macrophages and
other immune cells to destroy the tumor. Many cytokines and bacterial compounds can achieve
this in vitro, although the side effects are usually too severe when replicated in vivo. The key is
to find a compound that will have minimal or easily managed side effects in the patient.
Immunotherapy using macrophages has been used in the past decades and new approaches are
being developed every year.147,148 Early immunotherapy established a good foundation for better
cancer therapies and increased patient survival rates.149
Some approaches to cancer immunotherapy are the use of cytokines or chemokines to
recruit activated macrophages and other immune cells to the tumor site and allow the tumor cells
to be recognized as foreign and destroyed.150,151 IFN- α and IFN-β have been shown to inhibit
tumor progression by inducing differentiation and apoptosis.152 Also, IFN treatments are antiproliferative and can increase S phase time in the cell cycle.153,154 Zhang (2002) performed a
study in nude mice in which they used IFN-β gene therapy to target human prostate cancer cells.
Their results show that adenovirus-delivered IFN-β gene therapy involves macrophages and
helps suppress growth and metastasis.155
Another cytokine that can be used in cancer immunotherapy is macrophage inhibitory
factor (MIF). MIF is usually found in solid tumors and its presence usually means poor
prognosis. MIF, as its name describes, inhibits aggressive macrophage function, and therefore
causes macrophages to express an M2 response. An M2 response can aid tumor growth and
progression. Simpson, Templeton & Cross (2012) found that MIF induces differentiation of
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myeloid cells, macrophage precursors, into a suppressive population of myeloid cells that
express an M2 response. By targeting MIF, they were able to deplete this suppressive population
of macrophages and inhibit their growth and thus control tumor growth and metastasis.156
The chemokine receptor type 2, CCR2, is crucial to the recruitment of monocytes to
inflammatory sites and it has been shown as a target to prevent the recruitment of macrophages
to the tumor site, thus preventing angiogenesis and metastasis. Sanford and colleagues (2013)
studied a novel CCR2 inhibitor (PF-04136309) in a pancreatic cancer mouse model, showing
that the CCR2 inhibitor depleted monocyte/macrophage recruitment to the tumor site and
decreased tumor growth, metastasis, and increased antitumor immunity.157 Another recent study
showed that macrophages co-cultured with 10 different human lung cancers upregulated CCR2
expression. Moreover, they showed that using a CCR2 antagonist in a lung cancer mouse model
reduced tumor growth and metastasis.158
Other studies have used liposomes to deliver drugs to deplete M2 macrophages from
tumors and to stop angiogenesis. Cancer cells that express high levels of IL-1β grow faster and
induce more angiogenesis in vivo. Kimura and colleagues (2007) found that macrophages
exposed to tumor cells expressing IL-1β produced higher levels of angiogenic factors and
chemokines such as vascular endothelial growth factor A (VEG-A), IL-8, monocyte
chemoattractant protein 1, etc. When they used clodronate liposomes to deplete macrophages,
they found fewer IL-1β-producing tumor cells. They also found that by inhibiting NF-κB and
AP-1 transcription factors in the cancer cells, tumor growth and angiogenesis were reduced,
which may suggest that macrophages that are found near the tumor site may be involved in the
stimuli that allow macrophages to promote tumor growth and angiogenesis.159
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Compounds such as methionine enkephalin (MENK) have anti-tumor properties in vivo
and in vitro. MENK has the ability to polarize M2 macrophages to M1 macrophages by downregulating CD206 and arginase-1 (M2 markers) while upregulating CD64, MHC-II, and the
production of nitric oxide (M1 markers). MENK can also upregulate TNF-α and down-regulate
IL-10.160
Recent studies have focused on bisphosphonates as a potential inhibitor of M2
macrophages. Bisphosphonates are commonly used to treat metastatic breast cancer patients to
prevent skeletal complications such as bone resorption.161 While bisphosphonates stay in the
body for only short periods of time, they can target osteoclasts, cells in the same family as
macrophages, due to high affinity for hydroxyapatite. Once bisphosphonates bind to the bones,
the bone matrix internalizes the bisphosphonates by endocytosis and once in the cytoplasm,
bisphosphonates can inhibit protein prenylation, an event that prevents integrin signaling and
endosomal trafficking, forcing the cell to go apoptotic. Until recently, it was unknown whether
bisphosphonates could target tumor associated macrophages, but a recent study by Junankar et
al. has shown that macrophages uptake nitrogen-containing bisphosphonate compounds by
pinocytosis and phagocytosis, events that do not occur in epithelial cells surrounding the
tumor.162 Forcing TAMs to go apoptotic may reduce angiogenesis and metastasis.
Additional approaches to cancer immunotherapy include the use of biomaterials that may
elicit an immune response. Cationic polymers are used in immunotherapy because once
dissolved in water they can react with nucleic acids, adjuvants, etc. Chen et al. (2010) used
cationic polymers including PEI, polylysine, cationic dextran and cationic gelatin to produce a
strong Th1 immune response. They were also able to induce proliferation of CD4+ cells and to
induce secretion of IL-12 in macrophages, a cytokine produced by M1 macrophages.160 Huang
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and colleagues (2013) also used biomaterials to modulate TAMs to an anti-tumor response by
targeting TLR4. This study found that TAMs were able to polarize to an M1 phenotype and
express IL-12. They found that these cationic molecules have direct tumoricidal activity. They
were also able to show tumor reduction in mice.163
Cancer immunotherapy approaches using macrophages
Type

Name

Cytokine/
chemokine

Result
Inhibit tumor progression

IFN- α and IFN-β

Induce apoptosis in cancer cells
Induce differentiation of monocytes to macrophages
Prevents recruitment of monocytes/macrophages to the

CCR2
Anti-MIF shRNA
Inorganic
molecules

tumor site
Depletes M2 macrophage population from tumor site
Polarizes macrophages from M2 to M1

MENK

Downregulates CD2016, arginase 1, and IL-10
Upregulates CD64, MHC-II, TNF-α, and nitric oxide
Induce apoptosis in TAMs

Bisphosphonates

Reduce the number of infiltrating TAMs to the tumor site
Impairs angiogenesis

Cationic polymers

Induce a Th1 response

(PEI, polylysine, cationic dextran

Induce proliferation of CD4+ cells

and cationic gelatin)

Induce upregulation of IL-12 in macrophages

Vesicles

Deplete IL-1β producing cancer cells
Liposomes

Inhibit production of angiogenic factors (VEGF-A, IL-8,
monocyte chemoattractant protein 1)

Table 5- 1. Cancer immunotherapy approaches using macrophages
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Conclusion
Macrophages play an important role in tumor progression and metastasis because of the
plasticity they express during activation, especially in vivo. Depending on the signals present in
the tumor microenvironment, macrophages can express pro-inflammatory (M1 phenotype) or
anti-inflammatory (M2 phenotype) responses. The tumor microenvironment can polarize
macrophages towards an M2 response, an anti-inflammatory response, which can lead to tumor
progression, angiogenesis, and metastasis. M2 macrophages resemble tumor associated
macrophages (TAMs) which help recruit blood vessels at the tumor site and allow the tumor
cells to invade other tissues.
It is obvious that macrophages play a significant role in cancer progression, and
immunotherapies involving macrophages should be considered in the treatment of this disease.
The polarization of macrophages towards an M1 response with minimal side effects may prove
to be a powerful therapy against solid tumors. Inflammatory signals such as LPS or TNF-α can
easily polarize macrophages towards an M1 phenotype in vitro. However, use of substances such
an LPS and TNF-α in vivo exacerbate a whole-body inflammatory response involving cells of
both the innate and adaptive immune systems. They can cause fever and inflammation in several
tissues including the mucosal surfaces and the lungs. These inflammatory signals are highly
cytotoxic as well.164–166 This can be detrimental to cancer patients and compromise their health.
Current approaches to cancer immunotherapy using macrophages involve the use of
macrophage-granulocyte colony-stimulation factor (GM-CSF), cytokines and chemokines such
as MIF and interferons (IFN-α and IFN-β), and vaccines and biomaterials that can elicit immune
responses. These approaches have been shown to reduce tumor size and angiogenesis, recruit
immune cells to the tumor site, and prevent the polarization of macrophages to an M2 phenotype.
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Because immunotherapy requires the activation of the immune system, it is difficult to
find a cytokine, chemokine, compound, or biomaterial that will not produce some side effects.
However, because macrophages belong to the innate immune system and exhibit proinflammatory and anti-inflammatory properties, they are ideal immunotherapy candidates.
Further work is needed to identify substances and protocols that can adeptly re-educate
the immune system to attack cancer cells, prevent angiogenesis and metastasis, and to protect the
host from developing a damaging inflammatory response.
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APPENDIX 1: How Does the Tumor Microenvironment Affect Macrophage Aggressiveness?

The following appendix contains data that accompanies a published abstract in Cancer Research.
These data were presented at the American Association for Cancer Research Annual Meeting in
2014. I have modified the abstract to reflect recent changes in macrophage nomenclature.

Abstract
The immune system plays an important role in the development and progression of
cancer. In fact, immune cell infiltration can affect malignancy progression and metastasis.
Infiltration of macrophages to the tumor site has been shown to account for more than 50% of
the tumor mass in some breast cancers suggesting macrophages have a significant role in tumor
progression. Macrophages are cells derived from the myeloid lineage and belong to the innate
immune system. They differentiate from blood monocytes in tissue and one of their main
functions is to phagocytose microbes and clear cellular debris. Macrophages also play an
important role in inflammation and the resolution of inflammation. They exhibit a variety of
responses depending on the type of stimuli they receive, varying from pro-inflammatory to antiinflammatory. Two major macrophage phenotypes have been proposed: M1 and M2. M1
macrophages, or classically activated macrophages, show a pro-inflammatory profile that is
characterized by aggressive phagocytosis and anti-microbial properties. M2 macrophages, also
known as alternatively activated macrophages, exhibit immunomodulatory, repair, and
angiogenic properties. This project explored macrophage function by studying the
aggressiveness of macrophages exposed to different cancer cell lines (Raji, H460, MCF7, MDAMB-231, HT-29, SW620, and PC3) and their spent media. We used U937-derived macropahges

90

and as phagocytes. Macrophage aggressiveness was measured through flow cytometry by
quantification of macrophage engulfment rates of fluorescent spherical beads. We found that
cancer cell lines with higher aggressiveness had a more radical suppression of macrophage
engulfment (81% engulfment reduction compared to control) than less aggressive cell lines (1%
engulfment reduction compared to control). We also found that spent media had a lower effect
on macrophage engulfment overall, indicating cell to cell contact is important to suppress
macrophage engulfment. Spent media from aggressive cell lines had a similar effect to the cells
themselves, suggesting cytokine and vesicle communication. We also studied how these cell
lines affected macrophage polarization by qPCR, finding that lower engulfment rates correlate
with an M2 cytokine profile (high IL-10, low IL-12) and higher engulfment rates correlate with
an M1 cytokine profile (low IL-10, high IL-12). Further studies will help us understand more of
the signals that cancer cells give to their environment to prevent macrophage engulfment and to
help maintain an M2 phenotype.
Materials and Methods
Cell lines and culture
U937, Raji, H460, HT-29, MCF7, MDA-MB-231, SW620, and PC3 cell lines were
purchased from ATCC. All cell lines were authenticated by STR analysis. We cultured U937,
Raji, and H460, HT-29, and PC3 cell lines in RPMI 1640 supplemented with 10% FBS and
2mM L-glutamine and grown at 37℃ with 5% CO2. MCF7, MDA-MB-231, and SW620, cell
lines were cultured in DMEM supplemented with 10% FBS and 4mM L-glutamine grown at
37℃ with 5% CO2. To obtain spent media, we cultured Raji, H460, MCF7, MDA-MB-231, HT29, SW620, and PC3 in their respective complete medium for 48 hours. We collected the spent
media and centrifuged it at 300 x g for 15 minutes to pellet cells and cellular debris. The
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supernatant was used in the experiments. Normal mononuclear lymphocytes were separated from
whole blood using lymphocyte separation medium, then washed and resuspended in RPMI 1640
medium (supplemented with 20% human serum from the blood donor). Spent media was
collected by collecting the media after 48 hours of culture and centrifuging it at 300 x g for 15
minutes to pellet cells and cellular debris. The cellular pellet was used as cells in the
experiments.
Preparation of Macrophages
We stimulated U937 cells, a monocytic cell line, with phorbol 20nM 12-myristate 13acetate (PMA) for 24 hours to allow for differentiation. After 24 hours, we changed media and
cultured the attached cells for an additional 24 hours. We detached the cells by scrapping and
resuspended them at 1x106 cells/mL and dyed them with eFluor670 proliferation dye
(eBioscience) following manufacturer’s instructions.
Engulfment Assay
We incubated differentiated U937 cells with either Raji, H460, MCF7, MDA-MB-231,
HT-29, SW620, or PC3 cancer cells or their spent media for 48 hours. For the co-culture with
cancer cell lines, we used 12- well plates, placing a 0.4uM trans-permeable well inserts and
adding 5x105 differentiated dyed U937s at the bottom of the well and the 5x105 cancer cells on
top of the trans-permeable well. For the spent media treatment, we placed 5x105 differentiated
dyed U937s at the bottom of the wells of a 12-well plate and added 500uL of spent media from
either Raji, H460, MCF7, MDA-MB-231, HT-29, SW620, PC3, or normal lymphocytes. After
48 hours of incubation, we removed the trans-permeable wells and added 75 uL of FBS-coated
PE-conjugated microspheres (beads) and incubated for 1 hour. To coat the beads in FBS, we
resuspended 1 drop of beads into 4mL of FBS and incubated for 30 minutes. After incubating the
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U937 cells with beads for 1 hour, we detached the U937s from the wells using cell scrapers.
Cells were washed 3X to remove medium and beads that were not phagocytosed.

Figure A1- 1. Diagram of the macrophage engulfment assay.

Flow Cytometry Analysis
U937s were analyzed for bead engulfment using BD FACSCanto flow cytometer. 1x104
events were collected per sample. We first gated on APC+ cells, which represented U937 cells,
and then gated on PE+ cells. APC+PE+ cells represent U937 cells that engulfed at least one bead.
The population of APC+PE+ cells can be further gated into 1 bead, 2 beads, and 3+ beads,
depending on their fluorescence. The more beads the macrophage engulfs, the more aggressive
or inflammatory it is.
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Figure A1- 2. Flow cytometry analysis of the engulfment assay.
The top histogram (gate P4) represents cells that are APC+. The bottom histogram is derived from gate P4 and
represents cells APC+PE+. The peaks represent cells with either 1, 2, or 3+ beads engulfed.

Gene expression analysis
RNA was extracted from the U937 cells using the RNAAqueous Total RNA Isolation Kit
following manufacturer’s instructions. RNA was stored at -80℃ until use. For qPCR, we used the
qScript XLT 1-Step RT-qPCR ToughMix (Quantabio) and IL-1B, IL-10, and IL-12 generic
Taqman primers (ThermoFisher). We used Actin as our primer control. We performed the qPCR
reaction in a StepOne Real Time PCR System (ThermoFisher) using the comparative qPCR
setting. We analyzed the raw data using the double delta Ct analysis comparing actin gene
expression to IL-1B, IL-10, and IL-12.
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Results
U937-derived macrophage engulfment is decreased when they are exposed to cancer cell spent
media and cancer cells
Total macrophage engulfment was reduced when we exposed U937-derived macrophages
to HT-29 spent media and cells, to MCF7 and MDA-MB-231 spent media and cells, Raji spent
media and cells, PC3 cells, and normal lymphocyte spent media (Figure A1-3).
3+ Bead engulfment population decreases when U937-derived are exposed to cancer cell spent
media and cancer cells
When we looked at the individual bead populations within the macrophages that engulfed
at least one bead, we notice that there is a significant decrease of bead engulfment in the 3+ Bead
population. As the 3+ Bead population decreases, the 1 Bead population either decreases as well
or increases. We believe this is because the macrophages are becoming less aggressive and
polarizing towards and anti-inflammatory profile, such as M2. We observed the most change in
colon cancer cell lines HT-29 and SW620, breast cancer cell lines MFC7 and MDA—MB-231,
prostate cancer cell line PC3, and Burkitt’s lymphoma cell line Raji. We observed an increase in
the 3+ Bead population in the normal lymphocyte cell treatment. This was expected as normal
cells wouldn’t induce immunosuppression in macrophages (Figure A1-4).
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Figure A1- 3. Quantification of U937-derived macrophage engulfment after treatment with conditioned media or
cells.
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Figure A1- 4. Quantification of bead population engulfment among treatments.
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U937-derived macrophages gene expression profile mimics M2 macrophages
Gene expression analysis by qPCR revealed that U937-derived macrophages show an
upregulation of IL-10 and downregulation of IL-1B and IL-12, consistent with an M2 phenotype
gene expression profile (Figure A1-5).
Conclusion
Macrophages have been shown to have a significant role in tumor progression. Research
has shown that the tumor microenvironment can affect macrophage behavior. In this study, we
demonstrated that cancer cells and cancer cell spent media decreased macrophage engulfment,
especially in the 3+ bead population. We also found that the more aggressive the cancer cells, the
lower the engulfment rates. These findings open new prospective research on what components
from the media or the cancer cell metabolic products that mediate this lower engulfment rates. In
our experiments, cells that engulfed 3+ beads were characterized as M1. Further research using
qPCR may more clearly demonstrate and confirm the phenotypic changes in macrophages
caused by interactions with cancer cells. This may be used to better understand the influence of
the tumor microenvironment on macrophage phenotype
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APPENDIX 2: Prostate Cancer Microenvironment Modulates Macrophage Phagocytosis

The following appendix contains data that accompanies a published abstract in Cancer Research.
These data were presented at the American Association for Cancer Research Annual Meeting in
2015.
Abstract
Macrophages play an important role in the body's immune system. There are two main
phenotypes of macrophages, M1 and M2. M1 polarized macrophages participate in tumorcidal
activity and pro-inflammatory responses. M2 macrophages perform anti-inflammatory responses
and promote tissue repair, angiogenesis, and tumor growth. Macrophages within the vicinity of
cancer cells may be influenced by the microenvironment and change their gene expression
accordingly. Macrophages can express different cytokine profiles depending on their polarization
state (M1 or M2). We investigated whether macrophages exposed to cancer cells demonstrate a
M2 or M1 phenotype. We stimulated U937 cells with phorbol 12-myristate 13-acetate (PMA) for
24 hours to allow for adhesion and differentiation. We co-cultured PMA-stimulated U937
macrophages with PC3 and DU145 prostate cancer cell lines in a 1:1 ratio with a transpermeable
membrane to allow for cell to cell contact and communication, and with PC3 and DU145
conditioned media for 48 hours. We isolated the RNA from the treated macrophages and
performed qPCR to assess gene expression levels of the following cytokines: IL-10, a cytokine
demonstrating a M2 phenotype was upregulated by 10 and 15-fold for PC3 and DU145 cells
respectively and by 3 fold in both cell lines exposed to conditioned media. We also found a trend
of downregulation with the cytokines IL-1, IL-12, and TNF - alpha, which also depict a M2
phenotype. We also assessed macrophage function by measuring engulfment by flow cytometry.
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Treated macrophages were allowed to phagocytose fluorescent microbeads for 1 hour. Flow
cytometry analysis revealed that total bead engulfment decreased by up to 80% in macrophages
treated with PC3 cells. Moreover, the population of macrophages that engulfed 3+ beads
decreased significantly from both the cells and media treatments. Macrophages treated with
DU145 cells and spent media also showed a similar trend to macrophages exposed to PC3 cells.
The results show that macrophages exposed to PC3 and DU145 cancer cell lines polarized
towards an M2 phenotype and could be important in the success of cancer within the
microenvironment. Further research will reveal whether this process of a M2 polarization of
macrophages is mediated by cytokines and cell vesicles or other factors.
Materials and Methods
We stimulated U937 cells with phorbol 12-myristate 13-acetate (PMA) for 24 hours to
allow cell differentiation. After differentiation, U937s were stained with an APC cell
proliferation dye for flow cytometry purposes. We seeded PC3 and DU145 cells at 1x106
cells/mL with exosome-free RPMI 1640 for 96 hours, after which we collected the spent media
and spun it down, filtered it with a 0.2uM filter, and mixed it with ExoQuick TC (System
Biosciences). This mixture was incubated at 4°C overnight and then spun down at 1500 x g for
30 minutes. The supernatant was removed and the pellet was spun down again at 1500 x g for 15
additional minutes. All supernatant was then carefully removed and the pellet was resuspended
in 500uL of PBS and used immediately. PMA-stimulated U937 cells were incubated with 20uL
of exosome suspension solution for 1, 2, 3, 4, 5, 6, 12, and 24 hours at 37°C. After incubation
time, PE-fluorescent latex beads were added to the U937 cells for 1 hour and allowed the U937
cells to phagocytose the beads. After 1 hour, the U937 cells were washed twice with PBS to
detach removed any free beads. Then, the U937 cells were analyzed in a flow cytometer to
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account for bead engulfment. Also, we isolated RNA from the U937 cells and prepared it for 1step qPCR to analyze gene expression of IL-10 and IL-12.
Results
Flow cytometry analysis of the engulfment assay

Figure A2- 1. Flow cytometry analysis of the engulfment assay.
Cells that are APC+PE+ are selected and a histogram plotted to show the different PE peaks observed. The
difference in PE florescence account for macrophages engulfing either 1, 2, or 3+ beads.

Macrophage engulfment decreases when exposed to either DU145 or PC3 cells but not when
exposed to spent media
We observed that macrophage engulfment did not change when exposed to PC3 or
DU145 spent media, but it significantly decreased when the prostate cancer cell lines were in
direct contact with the macrophages. This may indicate that something on the membrane of the
prostate cancer cell lines, rather than a secreted protein, is signaling for macrophages to decrease
phagocytosis (Figure A2-2).

103

C e ll C o n t a c t T r e a t m e n t

S p e n t M e d ia T r e a t m e n t

**
80

p =0 .7 6 1

60

p =0 .8 0 1 3
40

20

T o ta l e n g u lfm e n t

T o ta l e n g u lfm e n t

80

**

p =0 .0 0 5 1

p =0 .0 0 2 1

60

40

20

0

0
C o n tro l

PC3

D U 145

C o n tro l

PC3

D U 145

Figure A2- 2. Engulfment quantification of macrophages exposed to either PC3 or DU145 spent media or cells.

Macrophage engulfment decreases after 5 hours of treatment with prostate cancer-derived
exosomes
We observed that when we exposed macrophages to exosomes, total phagocytosis
decreased around 5 hours with both the PC3 and DU145-derived exosomes. After that time
frame, macrophages regain normal phagocytic capabilities. This suggests that exosomes be
suppressing macrophage function in 5 hours after treatment, after which macrophages recover
(Figure A2-3).
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Figure A2- 3. Macrophages exposed to PC3 or DU145-derived exosomes over a period of time.
We observe that at 5 hours after treatment there is a decrease in macrophage engulfment.

Aggressive engulfment (3+Bead population) significantly decreases after 4-6 hour treatment with
prostate cancer-derived exosomes
The population of macrophages that engulfed 3+ Beads significantly decreased after 4-6
hours of treatment with exosomes derived from PC3 and DU145 cell lines. After that time frame,
macrophages regain their normal phagocytic capacity (Figure A2-4).

105

A

B

3 + B e a d s E n g u lf m e n t
P C 3 d e r iv e d E x o s o m e T r e a t m e n t

3 + B e a d s E n g u lf m e n t
D U 1 4 5 d e r iv e d E x o s o m e T r e a t m e n t

***
p =0 .0 0 0 5

100

*

p =0 .0 1 1 8

80

T o ta l e n g u lfm e n t

T o ta l e n g u lfm e n t

100

*

p =0 .0 1 5 1

60
40
20

***

80

p =0 .0 0 0 6

60
40
20
0

rs
u

rs

o
h

o
2

4

h
2
1

6

h

o

u

u

rs

rs

rs

u
o
h

5

4

h

o

u

rs

rs

u

3

h

o

u

u
2

h

o

o
h

1

C

o

n

tr

o

r

l

0

T im e

C

o

n

tr

o

l
1

h

o

u

r

2

h

o

u

rs
3

h

o

u

rs
4

h

o

u

rs
5

h

o

u

rs
6

h

o

u

rs

1

2

h

o

u

rs

2

4

h

o

u

rs

T im e

Figure A2- 4. The population of aggressive macrophages (3+Beads) exposed to PC3 or DU145-derived exosomes
over time.
We observe that macrophage engulfment decreases between 3-5 hours after adding PC3-derive exosomes and at 5
hours after adding DU145-derived exosomes.

Gene expression shows an upregulation of IL-10 and a decrease of IL-12 in macrophages
exposed to DU145-derived exosomes
Consistent with the engulfment data shown above, we observed that macrophages
exposed to DU145-derived exosomes show an upregulation of IL-10 and downregulation of and
IL-12 at 4 hours, mimicking an M2 phenotype gene expression profile. (Figure A2-5).
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Figure A2- 5. qPCR gene expression analysis of macrophages exposed to DU145-derived exosomes at 2 and 4 hours
showing an increase of IL-10 and IL-12 at 4 hours.

Conclusions
Macrophages are immune cells that have the ability to destroy tumors given the right
signals (M1 phenotype). In the tumor microenvironment, however, macrophages “polarize” into
a tumor promoting M2 phenotype. These tumor-associated macrophages (TAM’s) play a
significant role in tumor progression by facilitating metastasis and angiogenesis. Exosomes are
small vesicles secreted by cells that contain parts of the genome, some protein, and large
amounts of RNA, including miRNA. Exosomes secreted by one cell are able to distribute their
contents into another cell, and thus mediate cellular communication. Of special interest is the
exchange of miRNA. miRNA is able to silence genes involved in immune response, and may
thereby play a role in the silencing of M1-phenotypic genes in macrophages U937 cells that were
exposed to prostate cancer exosomes have a reduction in their phagocytic capacity between 3-6
hours of exosome treatment. Phagocytosis resumes to normal levels 6-24 hours after exposure.
Gene expression analysis suggests that these macrophages may be changing their phenotype
towards an M2 profile. These are preliminary results are interesting and further investigation will
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elucidate the phenotypic changes these macrophages may be going through in the presence of
exosomes.
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APPENDIX 3: Oxidants and Antioxidants: A Question of Balance

The following appendix contains unpublished data from a study done on the role of antioxidants
in cell response against oxidative stress and reactive oxidative species (ROS). This data was also
presented at the American Association for Cancer Research annual meeting in 2013 as
“Differences in cellular antioxidant activity in Burkitt's lymphoma and normal human
lymphocytes.”

Abstract
Cancer is a disease characterized by the uncontrolled growth of cells and invasion of
these cells to other tissues. Less than 10% of all cancer mutations are caused by genetic factors
while most mutations arise because of environmental factors. Environmental factors such as
smoking, poor diet and obesity, alcohol, etc are known to trigger oxidative stress. Oxidative
stress occurs when the concentration of reactive oxygen species (ROS) exceeds cellular
antioxidant capacity. This in turn leads to oxidative damage and DNA mutations. Cells, however,
have an antioxidant defense system that alleviates the effects of oxidative stress by preventing
ROS from being formed or by stopping their damaging effects. A major part of this defense
system is called the Antioxidant Response Element (ARE) which is located upstream of the
promoter region of antioxidative and cytoprotective genes. The ARE is activated when oxidative
stress occurs. Cells can also uptake antioxidants from their environment through passive and
active transport when needed. The role of antioxidants is not to remove oxidants entirely, but to
reduce them to sub-lethal levels within the cell. Diet plays an important role as a preventive
measure against diseases caused by ROS. In this study, we established a method to investigate
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the relationship between cell damage and nutrient uptake after exposing normal and cancer cells
to a simulated oxidant environment (that induced ROS) and then to an antioxidant rich
environment. We incubated Raji cells (Burkitt ’s lymphoma) and normal human lymphocytes
with 20mM AAPH (2 2′-azobis(2-amidinopropane) dihydrochloride) and then exposed them to
different known antioxidants namely, L-ascorbic acid, α-tocopherol, α-lipoic acid, glutathione,
and resveratrol for 10, 20, 45, and 60 minutes. We analyzed the cell lysates or antioxidant
activity after incubation with antioxidants using the oxygen radical absorbance capacity assay
(ORAC) and measured for antioxidant activity. Results show that Raji cells have significantly
higher antioxidant activity after exposed to an oxidant environment than when exposed to only
an antioxidant environment (p-values > 0.05). On the other hand, normal human lymphocytes
maintain relatively similar antioxidant activity when exposed to an oxidant followed by exposure
an antioxidant environment, even when stimulated to undergo cell division (p-values <0.05).
These results suggest that normal human lymphocytes are able to quench ROS quickly and are
able to protect their DNA from damage and subsequent mutations, whereas Raji cells lack this
mechanism and need to absorb more antioxidants from the environment, presumably because
they are unable to produce enough antioxidants themselves. These results may help explain why
cancer cells, which are usually depleted of antioxidants, are found to use antioxidants to protect
themselves from chemotherapy drugs.
Introduction
As recently as 2011, cancer was still the second highest killer in the United States, after
cardiovascular disease 167. However, strong correlations have been observed between lifestyle
and cancer incidences. According to the American Cancer Society, tobacco use is responsible
for at least 30% of all cancer deaths and about 87% of lung cancer deaths, while alcohol

110

consumption increases the risk of liver, breast and colorectal cancers 82. Diet and exercise also
affect cancer risk where an estimate of 1 out of 3 occurrences of cancer in the United States are
linked to obesity, poor nutrition or lack of physical activity 82. Obesity plays the biggest role out
of these three, contributing to 14% to 20% of all cancer-related deaths 82. These figures suggest
that in most cases cancer is a preventable disease and that everyday lifestyle choices can aid in
the reduction of cancer incidences.
The process of carcinogenesis starts when normal cells accumulate mutations that cause
cells to: grow uncontrollably, reject cellular signals that could stop their growth, resist apoptosis,
induce angiogenesis, and produce abnormalities in their DNA and chromosomes, etc. 1,168–170.
Less than 10% of all mutations that lead to cancer are caused by inherited genetic factors. Most
mutations arise as a result of environmental factors 171.
Environmental factors such as smoking, poor diet and obesity, alcohol, radiation,
carcinogens, etc can trigger oxidative stress. Oxidative stress takes place when the concentration
of reactive oxygen species (ROS) exceeds cellular antioxidant capacity 172. This in turn leads to
oxidative damage and DNA mutations 173.
ROS are partially reduced forms of oxygen that are often produced naturally in the cell as
a by-product of metabolic processes involving oxygen. These processes include the electron
transport chain during cellular respiration. ROS participate in cell signaling and are needed for
activation of transcription factors and for the control of expression of tumor suppressor genes
such as p53 and Rb 173,174. In order to maintain cellular equilibrium, ROS must be produced and
consumed at approximately equal rates 173.
Normal cellular processes are estimated to produce about 2 x 1010 superoxide and
hydrogen peroxide compounds per cell per day 175. However, ROS can also be induced as a
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result of exposure to ultraviolet light, radiation, and smoke 176. The increase of ROS possesses
the potential to cause oxidative injury to macromolecules such as nucleic acids, proteins and
lipids. Cellular damage caused by ROS can lead to necrosis and ATP depletion, which can
prevent apoptosis, one of the “symptoms” of cancer 177. Oxidative stress has also been linked to
other diseases such as atherosclerosis, Parkinson’s disease, diabetes and Alzheimer’s disease 178.
Exercise can also dramatically elevate the level of ROS in the body 179. During exercise,
mitochondria in skeletal muscle produce nitric oxide synthase (NOS), an enzyme that produces
an intermediate of nitric oxide (NO-), a highly reactive molecule. NO- and O2 (in radical form)
can react to produce peroxinitrite, ONOO-, which is a powerful oxidant that can break the ROS
cellular equilibrium and can lead to DNA injury. Physical activity can also activate leukocyte
infiltration, which may lead to inflammation due to ROS release. Leukocytes, especially
phagocytes, are large producers of ROS that kill bacteria and foreign antigens but can also cause
tissue damage. Research has shown that there is an increase of neutrophil infiltration into
skeletal muscle after strenuous physical activity, which elevates normal levels of ROS in the cell
180

. Research also confirms higher ROS levels in humans after downhill running 179,181,182.
Cells, however, have an antioxidant defense system that alleviates the effects of oxidative

stress by preventing ROS from being formed or by removing them or neutralizing them from the
cell 183. This defense system is called the Antioxidant Response Element (ARE) which is a
transcription factor binding site located upstream of the promoter region of antioxidative and
cytoprotective genes. A family of transcription factors called NFE2 activates the ARE. NFE2 is
usually bound to Keap 1, a cytoplasmic protein. Under normal conditions, Keap1 induces the
ubiquitination of NFE2, which has a half-life of 20 minutes. Under oxidative stress, cysteine
residues in Keap1 are disrupted and NFE2 is released. NFE2 migrates to the nucleus, where it
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binds to the ARE and induces the transcription of several antioxidant-producing enzymes 184.
Cells can also uptake antioxidants from their environment through passive and active transport
when needed 185.
Substances such as L-ascorbic acid (vitamin C), α-Tocopherol (vitamin E), resveratrol,
glutathione, and lipoic acid serve as antioxidant sources against oxidative stress and therefore are
thought to have chemopreventive properties.
L-ascorbic acid (vitamin C) has proven to be one of the most successful chemopreventive
compounds for non-hormone-dependent cancers. Vitamin C is a water-soluble compound that is
absorbed by cells through passive and active transport (active transport accounts for the greater
portion of vitamin C accumulation in cells) 186. In humans, vitamin C must be acquired from diet
due to lack of gulonolactone oxidase, an enzyme that synthesizes L-ascorbic acid 187. Studies
show that higher ingestion of vitamin C has a high correlation with lower risk for pancreatic,
cervical, and colorectal cancer 188. Also, higher intake of vitamin C during pregnancy decreases
risk of brain tumors during childhood. Vitamin C also aids in the regeneration of vitamin E and
other antioxidants 188.
Vitamin E, a lipophilic antioxidant referred to a group of tocopherols and tocotrienols,
has also shown chemopreventive properties. Mostly absorbed through active transport using
lipoprotein channels, vitamin E protects cell membranes from lipid peroxidation and quenches
ROS when fat is oxidized 189,190. The most abundant form of vitamin E in cells is α -tocopherol
and although has the highest antioxidant activity of all vitamin Es, δ-tocopherol and λtocopherol are more effective at free radical quenching and therefore are considered the types of
vitamin E that account for cancer preventive properties 191.
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Glutathione is the major soluble endogenous antioxidant found in cells. It is a simple
compound made of glutamate, cysteine, and glycine. Its role is to scavenger free radicals and
peroxides. Glutathione or its precursors are absorbed by active transport, using gammaglutamyltransferase, and passive transport, which is dependent on sodium ions 192,193.
Glutathione is usually found in its reduced form and is rapidly consumed when oxidants are
produced, maintaining cellular equilibrium 194. Glutathione has several other functions including
the regeneration of vitamin C and vitamin E, DNA synthesis and repair, and it is often involved
in cell proliferation and death 193. Under oxidative stress, normal cells respond by upregulating
the production of glutathione. In cancer cells, glutathione production is unregulated where some
cancer cell lines exhibit glutathione depletion and other cancer cell lines such as bone marrow,
breast, lung, larynx, and colon have shown increased levels of glutathione which protects them
from the harmful effects of chemotherapy drugs 193,194
Lipoic acid, called the “universal antioxidant”, is a small amphipathic molecule with two
thiol groups that can be oxidized or reduced 195. The reduced form of lipoic acid or dihydrolipoic
acid (DHLA) is the major form of lipoic acid that reacts with ROS, however, the oxidized form
can also inactivate free radicals. Both forms of lipoic acid are able to regenerate vitamin C and
vitamin E. Lipoic acid is mostly obtained from diet but cells can synthesize it in small amounts
if needed. Because of its amphipathic properties, lipoic acid can easily cross biological
membranes and protect the cell from oxidants in every cell compartment 195. Lipoic acid has
been shown to protect cells from gamma radiation in mice 196, and to induce apoptosis in murine
melanoma cells, ovarian epithelial cancer cells, and breast cancer cells without inducing
apoptosis in normal non-transforming cells 197–200.

114

Resveratrol is an antioxidant found in the skin of grapes, berries, and other fruits. It is a
phytochemical produced by plants in response to a fungal infection 201. Resveratrol has been
found to be a preventive compound for several pathologies such as cardiovascular disease, viral
infections, Alzheimer’s disease, and cancer. Resveratrol has been shown to stop tumor initiation,
promotion, and progression 201,202. Resveratrol has the ability to quench ROS such as superoxide
and hydroxyl radicals. It especially protects the mitochondria, an organelle that produces high
concentrations of ROS 203. Resveratrol can be absorbed by cells through passive transport. It can
also be absorbed by carrier-mediated transport as resveratrol associates with several serum
proteins to enter the cells. This allows resveratrol to be readily absorbed by cells 202.
The role of antioxidants is not to remove oxidants entirely, but to maintain them at
optimum levels within the cell. The importance of natural dietary substances is promoted as an
effective precursor in preventative measures regarding illness and health deficient symptoms due
to ROS presence within the body. Finding the right balance between oxidants and antioxidants in
the cell is important to maintain proper cellular health.
This study establishes a method to investigate the relationship between cell damage and
antioxidant uptake after exposing normal and cancer cells to a simulated oxidant stress
environment. We hypothesize that cells previously exposed to an oxidant agent and then to an
antioxidant environment will exhibit higher antioxidant activity than cells exposed to an
antioxidant environment only, suggesting that diet and exercise combined provide the best way
to protect our cells from the damaging effects of oxidative stress.
Materials and Methods
Chemicals
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RPMI 1640 medium, Fetal Bovine Serum, and Hank's Balanced Solution were purchased
from Thermo Scientific (Logan, UT). 2,2′-azobis (2-aminidopropane) dihydrochloride (AAPH)
was purchased from Wako Chemicals USA, Inc. (Richmond, VA). Fluorescein-sodium salt and
phosphate buffered saline (PBS), 200 Proof Ethanol, L-Ascobic acid, Resveratrol, α-Tocopherol,
glutathione, and α-lipoic acid were purchased from Sigma-Aldrich, Inc. (Milwaukee, WI).
Trolox (6-hydroxy-2,5,7,8-tetramethyl-2-carboxylic acid) was purchased from Enzo Life
Sciences, Inc. (Plymouth, PA). Dimethyl sulfoxide (DMSO) was purchase from purchased from
EMD Chemicals (Billerica, MA).
Materials
Costar 96-well black clear bottom plates were purchased from Corning Inc. (Corning,
NY). Raji cells (Burkitt’s lymphoma cell line) were obtained from the American Type Culture
Collection (ATCC) (Manassas, VA).
Equipment
Readings were taken in a BMG FLUOstar Optima microplate reader (BMG Laboratories,
serial #413-0225). Data was analyzed using Microsoft Excel and IBM SPSS Statistics.
Burkitt’s lymphoma cell culture
Raji cells (Burkitt’s lymphoma) were cultured in RPMI 1640 supplemented with 10% Fetal
Bovine Serum and kept in an incubator with 5% carbon dioxide at 37 ˚C.
Lymphocyte separation
Normal human lymphocytes were separated from whole blood using Lymphocyte
Separation Medium (LSM). Whole blood was obtained under IRB approval from young
volunteers (18-24 years-old). Heparinized whole blood was diluted in a 1:1 ratio with 1X
Hank’s Buffered Saline Solution (HBSS). Diluted blood was layered on top of LSM in conical
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vial and centrifuged at 800g for 20 minutes. The leukocyte-rich layer was removed and washed
with PBS. Leukocytes were re-suspended in RPMI 1640 medium supplemented with 20%
human serum and 3% LPS; and cultured for 24 hours to allow for monocyte differentiation and
attachment to the culture flask. Lymphocytes in suspension were removed from the flask,
washed with PBS, re-suspended in RPMI 1640 medium supplemented with 10% FBS, and used
immediately.
Sample preparation
L-Ascorbic Acid: 10mM. 0.0176g of L-Ascorbic acid was diluted in 10 ml PBS.
Resveratrol: 10mM. 0.0228g of resveratrol was diluted in 10ml of DMSO.
α-Tocopherol: 10mM. 0.0431g of α-Tocopherol was diluted in 10ml of 15% ethanol.
Glutathione: 10mM. 0.0307g of glutathione was diluted in 10ml of PBS.
α-Lipoic Acid: 10mM. 0.0206g of α-lipoic acid was diluted in 10ml of 15% ethanol.
Incubations
Lymphocytes and Raji cells at 1.0 x 106 cells/mL were incubated with the various
samples (ascorbic acid, tocopherol, resveratrol, glutathione, and lipoic acid) for 10, 20, 45, and
60 minutes. The cells were washed with PBS and lysed open by freeze-thawing. The lysate was
centrifuged at 15,300 g for 30 minutes. The supernatant was stored at -20°C until analysis using
the ORAC assay.
Simulation of Oxidative Stress assay
Lymphocytes and Raji cells at 1.0 x 106cells/mL were incubated with 19.9 mM AAPH
for 10 minutes to simulate oxidative stress. The cells were washed with PBS and re-suspended
in RPMI 1640 at 1.0 x 106cells/mL. The cells were incubated with the various samples (ascorbic
acid, tocopherol, resveratrol, glutathione, and lipoic acid) for 10, 20, 45, and 60 minutes and
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washed with PBS and lysed open. The lysate was centrifuged at 15,300 g for 30 minutes. The
supernatant was stored at -20°C. Note that lipoic acid was used in its oxidative form to account
for antioxidant capacity of cells when continuously exposed to an oxidizer that can be recycled.
ORAC assay
The Oxygen Radical Absorbance Capacity Assay was used to analyze all of our samples.
For this experiment, we used a modified ORAC based on published methods 204–206. The ORAC
assay measures the decay of fluorescence after exposed to a free radical initiator (AAPH). All
readings were taken using Costar 96-well black with clear bottom plates, with 20µ sample or
PBS, 200µL fluorescein, and 20µL AAPH in each well.
Readings were taken every 2 minutes for 90 minutes using a 485nm excitation filter and a
590 nm emission filter with a BMG FLUOstar Optima microplate reader.
Standard curve data
Trolox, a water-soluble analogue of vitamin E, was used as a control standard. To obtain
standard curves for each trial, Trolox was run at concentrations of 50µM, 25µM, 12.5µM. Data
from each standard curve was used to convert raw net area under the sample curve (net AUC)
values to Trolox Equivalents per liter (TE/L). Subsequent calculations converted TE/L to TE/L
per 1.0 x 106 cells.
Cytotoxicity
Cells at 1.0 x 106cells/mL and at 90% or higher viability were exposed to different
dilutions of 320mM AAPH (1:1, 1:2, 1:4, 1:8, 1:16, and 1:32) and incubated for 24 hours. After
24 hours of incubation, cell counts and cell viability counts were performed. The dilution 1:16
was found to maintain 90% cell viability and increase cell counts. We performed this incubation
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with dilutions of AAPH to eliminate the possibility of cells showing higher antioxidant uptake
because of cell membrane damage.
Results
All the following data are reported in Trolox Equivalents per litter per 1.0 x 106 cells
(TE/L/1.0 x 106 cells). Data from each sample was repeated four times, with 12 replicates for
each sample, giving a total of 48 results per sample.
We measured the antioxidant activity in Raji and normal lymphocytes after incubation
with L-ascorbic acid (vitamin C), α-tocopherol (vitamin E), glutathione, lipoic acid, resveratrol,
or PBS (control) and after oxidative treatment and followed by incubation with the mentioned
antioxidants (Table A1-1 and 2). Mean values are reported in Trolox Equivalents per liter per
1x106 cells (TE/L per 1x106 cells).
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Table A3-1
ANTIOXIDANT AND

TIME IN MINUTES

TREATMENT

10

20

45

60

L-Ascorbic

Incubation

1706.31

1812.53

1775.38

2080.73

Acid

Oxidative treatment

1964.62

3156.77

2783.21

2456.49

Incubation

2054.26

2238.43

1788.79

1512.96

Oxidative treatment

1816.45

1940.89

2827.29

2690.45

Incubation

1222.04

972.20

962.70

1042.55

Oxidative treatment

1891.67

2156.48

2600.05

2335.08

Incubation

4387.78

3639.42

4156.90

4820.41

Oxidative Treatment

2026.91

3995.61

4118.37

4425.34

Incubation

1487.16

1166.82

1266.43

1326.65

Oxidative treatment

1151.06

1124.58

1406.15

1802.59

Incubation

2016.38

2420.02

1753.53

2688.23

Oxidative treatment

1302.95

1751.83

1865.28

2208.59

α-Tocopherol

Glutathione

Resveratrol

Lipoic Acid

Control (PBS)

Table A3- 1. Antioxidant activity in normal lymphocytes after incubation with L-ascorbic acid (vitamin C), αtocopherol (vitamin E), glutathione, lipoic acid, resveratrol, or PBS and after oxidative treatment and followed by
incubation with the mentioned antioxidants
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Table A3-2
ANTIOXIDANT AND

TIME IN MINUTES

TREATMENT

10

20

45

60

L-Ascorbic

Incubation

1805.86 1629.22

1703.50

1803.69

Acid

Oxidative treatment

1603.81 3056.42

2608.09

3087.14

Incubation

1339.87 1292.38

1482.90

1475.00

Oxidative treatment

1767.28 2190.20

2329.61

2625.68

Incubation

2006.79 1614.80

1625.69

1743.60

Oxidative treatment

1884.03 2589.20

2209.45

2582.08

Incubation

2489.82 2608.60

2092.61

2587.45

Oxidative Treatment

3069.06 6227.59

5080.96

6284.72

Incubation

931.87

934.44

885.63

Oxidative treatment

1467.11 1617.89

1599.85

1504.90

Control

Incubation

2439.40 2159.70

2142.62

1889.55

(PBS)

Oxidative treatment

2079.44 2718.65

3011.89

3872.41

α-Tocopherol

Glutathione

Resveratrol

Lipoic Acid

895.75

Table A3- 2. Antioxidant activity measured in Raji cells after incubation with L-ascorbic acid (vitamin C), αtocopherol (vitamin E), glutathione, lipoic acid, resveratrol, or PBS. Values are shown in Trolox Equivalents per
liter per 1x106 cells (TE/L per 1x106 cells).
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Figures A3-1 and A3-2 show side by side the differences in cellular antioxidant activity of
lymphocytes and Raji cells after being exposed to an antioxidant environment, and after being
exposed to oxidative stress and to an antioxidant environment. Trends are similar with
lymphocytes and Raji cells, where antioxidant activity increases after the cells have been
exposed to oxidative stress (AAPH) compared to cells that have been exposed to antioxidant
environment only. Resveratrol registers the highest antioxidant activity. Lipoic acid was used in
its oxidized form to account for constant oxidative stress.
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Figure A3- 1. Differences in cellular antioxidant activity in Raji cells followed antioxidant incubation and oxidative
treatment + antioxidant incubation.
Continues in next page.
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Figure A3- 2. Differences in cellular antioxidant activity in Raji cells followed antioxidant incubation and oxidative

treatment + antioxidant incubation.
Continues in next page.
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Conclusion
This paper investigates the relationship between oxidative stress and antioxidant uptake
in Burkitt’s lymphoma compared to normal lymphocytes. We used L-ascorbic acid (vitamin C),
α-Tocopherol (vitamin E), glutathione, lipoic acid, and resveratrol as antioxidant sources for the
cells in concentrations that allowed for minimal cytotoxicity and were physiologically relevant
(data not shown).
When we used normal lymphocytes and measured the amount of antioxidant activity
present in our control sample, we observed that when cells are incubated with PBS they do not
change their antioxidant activity, which averages 2219.54 TE/L per 1.0 x 106 cells in one hour
(Table 1). When we exposed normal lymphocytes to the oxidative treatment (19.9mM AAPH
for 10 minutes), we observed a statistically significant decrease in antioxidant activity at 10 and
20 minutes (2-sided p-value=0.003, and 2-sided p-value=0.007 respectively) due to the oxidative
treatment. At 45 and 60 minutes, we observed no difference in antioxidant capacity in the cells
pre-treated with AAPH and the cells that were incubated with saline solution (2-sided pvalue=0.52, and 2-sided p-value=0.07 respectively), suggesting that the normal lymphocytes can
deal with oxidative stress between 20 and 45 minutes after being exposed to it, and that they are
able to obtain an oxidant-antioxidant balance.
Raji cells showed an average of 2157.82 TE/L per 1.0 x 106 cells in one hour. After
oxidative treatment, however, Raji cells demonstrated a continuous increase in antioxidant
capacity with time from 20 minutes on (2-sided p-value <0.001 at times 20, 45, and 60 minutes).
These results show that Raji cells have higher antioxidant activity with time than normal
lymphocytes after being previously exposed to oxidative stress, suggesting that Raji cells cannot
deal with oxidative stress as well as normal lymphocytes and cannot maintain a proper oxidant-
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antioxidant balance. It is important to understand that the balance between ROS and
antioxidants is critical in protecting the cell from oxidative stress; high antioxidant activity in the
cell may not always be beneficial, as it may mean that the cell has a deficiency in the recycling
antioxidant mechanism, which is involved in immune system regulation using the NF-κB
transcription factor 207.
Normal lymphocytes incubated with L-ascorbic acid show an average of 1843.74 TE/L
per 1.0 x 106 cells in one hour; whereas Raji cells show an average of 1735.57 TE/L per 1.0 x 106
cells in one hour. After oxidative stress, normal lymphocytes show a decrease in antioxidant
capacity at 10 minutes but then it significantly increases at 20 and 45 minutes (2-sided pvalue=0.003 and 0.004 respectively) to finally restore balance at 60 minutes compared to
incubation with L-ascorbic acid only. Raji cells, after oxidative treatment, show an increase in
antioxidant activity at times 20, 45, and 60 minutes (all 2-sided p-values <0.001), showing its
highest antioxidant activity at 60 minutes with 3087.14 TE/L per 1.0 x 106 cells. The antioxidant
capacity of the cell lysates seems to remain elevated from 20 minutes on, which again suggests
the uptake of L-ascorbic acid into the cells but the lack of a mechanism to control oxidative
stress.
Lymphocytes exposed to oxidative treatment and incubated with α-tocopherol (vitamin
E) had statistically significant increases in antioxidant activity at minutes 45 and 60 (2-sided pvalues 0.02 and 0.005 respectively) compared with lymphocytes incubated with α-tocopherol
only. Raji cells show a pattern similar to the one shown in our control sample (Figure 12) where
antioxidant activity increases with time.
Lymphocytes incubated with glutathione significantly increase their antioxidant capacity
when cells are exposed to oxidative treatment first. Raji cells incubated with glutathione show
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higher antioxidant activity than lymphocytes with the same treatment and show a similar trend to
lymphocytes when exposed to oxidative treatment before incubation with glutathione.
Resveratrol is the only compound we used that is not made by animal cells; therefore,
most of the antioxidant capacity shown in our readings comes from resveratrol that has been
absorbed by cells. Incubation of lymphocytes with resveratrol gives an average of 4251.13 TE/L
per 1.0 x 106 cells in one hour and incubation of lymphocytes with resveratrol after oxidative
stress gives an average of 3641.56 TE/L per 1.0 x 106cells in one hour, a difference that is not
statistically significant (2-sided p-value= 0.31). In figure 5 we observe that at 10 minutes
antioxidant activity is higher in incubation than in samples with oxidative treatment (2-sided pvalue <.0001) due to the nature of the oxidative treatment. Antioxidant capacity increases in the
samples with oxidative stress, however, at 20 minutes, and restores oxidant-antioxidant balance
with the incubation samples thereon. Raji cells show a different trend compared to normal
lymphocytes. Incubation with resveratrol averages 2444.62 TE/L per 1.0 x 106 cells in one hour
whereas incubation with resveratrol after oxidative stress averages 5165.58 TE/L per 1.0 x 106
cells in one hour. Significant increases in antioxidant capacity are seen at 20, 45, and 60 minutes
(2-sided p-values <0.001). In comparison with lymphocytes, Raji cells do not absorb as much
resveratrol as normal lymphocytes do (Table 1 and Table 2), however, after oxidative stress Raji
cells absorb much more resveratrol. Resveratrol is largely absorbed by the cell through passive
and carrier-mediated transport, which is what we observe when we use the ORAC assay to read
cytoplasmic antioxidant activity 202.
To test how cells would react to oxidative stress when constantly exposed to an oxidant,
we used an oxidized form of lipoic acid. Normal lymphocytes exposed to oxidized lipoic acid
show an average of 1311.76 TE/L per 1.0 x 106 cells in one hour. When we pre-exposed normal
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lymphocytes to AAPH and then to oxidized lipoic acid, we observe an average of 1371.09 TE/L
per 1.0 x 106 cells in one hour. The only significant difference is observed at 10 minutes, where
the cells exposed to AAPH and then to oxidized lipoic acid show lower antioxidant capacity than
cells just incubated with oxidized lipoic acid (2-sided p-value=0.04), which is expected. Raji
cells, however, showed a different trend. When Raji cells were incubated with oxidized lipoic
acid, the antioxidant capacity averaged 911.92 TE/L per 1.0 x 106 cells in one hour whereas the
when the Raji cells were treated with AAPH and then with lipoic acid the antioxidant capacity
averaged 1547.44 TE/L per 1.0 x 106 cells in one hour. We observed significant difference at
every time point (2-sided p-values= 0.002, <0.001, <0.001, and <0.001 for 10, 20, 45, and 60
minutes respectively).
Overall, our study shows that cancer cells cannot maintain balance after oxidative stress,
as we see that they increase and keep increasing antioxidant capacity over time. Normal cells
stop increasing their antioxidant capacity when they sense that the oxidative stress has been
reduced. Our study also shows that the differences we see between Raji cells and normal
lymphocytes with this oxidative treatment may suggest that cancer cells can increase their
antioxidant capacity when they are exposed to oxidative stress, a mechanism that may be
employed to protect themselves from the damaging effects of chemotherapy drugs.
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APPENDIX 4: Yeast Two-Hybrid Reveals Novel Proteins Interacting with TK1

The following appendix contains unpublished data from a yeast two-hybrid analysis that we
performed trying to find novel proteins interacting with TK1. We originally wanted to gain
preliminary data that would allow us to continue with our hypothesis that TK1 was found on the
membrane and wanted to see whether it could localize there through a protein-protein
interaction.

Yeast two-hybrid assay
We used the Matchmaker Gold Yeast Two-Hybrid system. In this two-hybrid system, the
libraries of prey proteins are expressed as fusions to the Gal4 activation domain (AD) and the
bait proteins are expressed as fusions to the Gal4 DNA binding domain (DNA-BD). When the
bait and prey proteins interact, the DNA-BD and the AD are brought into proximity and activate
the transcription of four independent reporter genes (AUR1-C, ADE2, HIS3, and MEL1). The
translation of these genes allow yeast to grow in SD –leu-trp-his-ade agar plates.

Figure A4- 1. Diagram of the Matchmaker Gold Yeast Two-Hybrid system.
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Vectors
For the library of prey proteins, we selected the Normalized Yeast Two-Hybrid cDNA
Library from Clonetech (catalog # 630481). The cDNA library was constructed using the
pGADT7-RecAB vector.

Figure A4- 2. Vector information from the Normalized Yeast Two-Hybrid cDNA Library from Clonetech.
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For the bait protein, we cloned a yeast codon optimized human TK1 sequence into a
pGBKT7 bait vector.
TK1 Sequence
The yeast codon optimized sequence for TK1 used is the following:
ATGTCCTGCATCAACTTACCTACCGTATTGCCTGGTTCTCCTTCAAAGACTAGAGGTC
AAATTCAAGTTATATTGGGTCCTATGTTCTCTGGTAAATCTACTGAATTGATGAGAA
GAGTTAGAAGATTCCAAATTGCTCAATACAAGTGTTTAGTTATTAAATACGCAAAGG
ATACAAGATACTCTTCATCTTTTTGTACTCATGATAGAAACACAATGGAAGCATTGC
CAGCTTGTTTGTTAAGAGATGTTGCACAAGAAGCATTGGGTGTTGCTGTTATTGGTA
TTGATGAAGGTCAATTTTTCCCAGATATCGTTGAATTTTGTGAAGCTATGGCAAATG
CTGGTAAAACTGTTATTGTTGCTGCATTGGATGGTACATTCCAAAGAAAGCCATTCG
GTGCAATCTTGAATTTGGTTCCATTGGCTGAATCAGTTGTTAAATTGACTGCAGTTTG
TATGGAATGTTTTAGAGAAGCTGCATACACTAAAAGATTGGGTACAGAAAAAGAAG
TTGAAGTTATTGGTGGTGCTGATAAGTACCATTCAGTTTGTAGATTATGTTACTTTAA
AAAGGCTTCTGGTCAACCAGCTGGTCCAGATAATAAGGAAAATTGTCCAGTTCCAG
GTAAACCAGGTGAAGCCGTAGCCGCAAGAAAGTTATTCGCCCCACAACAAATTTTA
CAATGTTCACCTGCCAAT
We transformed the pGBKT7-TK1 plasmid into the 1031 yeast strain and grew it in SDtrp selective medium. We then mated the pGBKT7-TK1 yeast with the cDNA library. We plated
the mated yeast in SD-leu-trp-his-ade agar plates and incubated at 30°C incubator for up to 1
week. The colonies that grew were then grown in SD-leu selective medium to be able to select
for the library plasmid only. The library plasmid was then extracted and transformed into E. Coli
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(DH5α strain) and grown in LB amp selective medium. The plasmids were isolated again and
sent for sequencing.
Primers
The primers used for sequencing were the following:
Forward: CTATTCGATGATGAAGATACCCCACC
Reverse: CAGAGGTTACATGGCCAAGATTG

Results and analysis
The results from sequencing were match to the human genomic and transcript database
using Basic Local Alignment Search Tool (BLAST). We checked that the sequencing matched
the coding region presented on the BLAST hits. We then used the ExPasy Translate tool to
translate the protein sequence in-frame using the pGDAT7-RecAB vector information provided
by Clonetech. The in-frame start codon can be found after this nucleotide sequence:
AGCGCCGCC.
In-frame amino acid matches were then aligned with the wild type protein sequence from the
BLAST hits. This allowed us to determine whether the library plasmids contained a true protein
hit.
We performed the yeast two-hybrid experiment three times and obtained a total of 106
yeast colonies. After analysis, we obtained 17 true hits, 4 of which are novel.
Dependency assays
We then performed dependency assays to determine whether authenticity of the hits. To
do this, we transformed the following into 1031 yeast:
•

Empty pGBKT7 vector with empty pGDAT7-RecAB
134

•

pGBKT7-TK1 with empty pGDAT7-RecAB

•

Empty pGBKT7 vector with library plasmid match

•

pGBKT7 vector with library plasmid match

We selected for yeast containing both plasmids by plating the transformed yeast on SD-leutrp agar plates. We then plated the yeast into SD-leu-trp-his-ade agar plates to select for true
interactors.
Novel proteins interacting with TK1
This is a list of the novel proteins that interact with TK1:
1. Ring finger protein 2 (RNF2)
2. G elongation factor, mitochondrial 2 (GFM2)
3. COP9 signalosome subunit 5 (COPS5)
4. DMRT like family A1 (DMRTA1)
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